{"study_id": 102354, "supplement_id": 863, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the efficacy and safety of aldafermin, an FGF19 analog, in patients with non-alcoholic steatohepatitis (NASH).", "results_summary": "Aldafermin demonstrated dose-dependent improvements in liver fat content, fibrosis biomarkers, and liver enzyme levels, but no significant histologic fibrosis improvement. Diarrhea was more common with the 3 mg dose, but overall adverse effects were comparable to controls.", "population_specificity": "Patients with non-alcoholic steatohepatitis (NASH).", "effective_dosage": "1 mg and 3 mg doses.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:51.715250+00:00"}
{"study_id": 102355, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to investigate hepatotoxicity induced by anti-TB drugs and assess demographic factors and retreatment outcomes, not specifically Alanine.", "results_summary": "The study found that female gender and weight loss were associated with hepatotoxicity from anti-TB drugs, but it did not evaluate Alanine.", "population_specificity": "Patients admitted to the infectious ward of Imam Khomeini Hospital with hepatotoxicity due to anti-TB treatment (April 2015\u2013February 2019).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:51.851245+00:00"}
{"study_id": 102353, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the effects of tenofovir disoproxil fumarate (TDF) on mother-to-infant transmission of HBV, including monitoring liver function markers such as alanine aminotransferase.", "results_summary": "The study found no significant differences in liver function markers, including alanine aminotransferase, between the TDF-treated and control groups. TDF significantly reduced maternal HBV DNA viral load and was associated with a lower risk of mother-to-infant HBV transmission.", "population_specificity": "Pregnant women with high HBV DNA viral loads.", "effective_dosage": "Not specified (TDF administered from 28 weeks gestational age to delivery).", "study_duration": "From 28 weeks gestational age to delivery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:52.184341+00:00"}
{"study_id": 102356, "supplement_id": 863, "safety_score": "30", "efficacy_score": 25, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, maximum tolerated dose, and antitumor activity of MEDI7247, an antibody-drug conjugate targeting the sodium-dependent alanine-serine-cysteine transporter 2, in patients with hematological malignancies.", "results_summary": "The study found that MEDI7247 caused significant adverse events, including thrombocytopenia, neutropenia, and anemia, limiting repeat dosing. Anticancer activity was observed in 16.4% of patients, but no correlation was found between ASCT2 expression and clinical response.", "population_specificity": "Adults with relapsed or refractory acute myeloid leukemia, multiple myeloma, or diffuse large B-cell lymphoma.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:53.328416+00:00"}
{"study_id": 102357, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the safety and efficacy of isatuximab combined with carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma.", "results_summary": "The study does not report findings related to Alanine; it focuses on treatment response and side effects of the Isa-KRd regimen, including elevated alanine aminotransferase as a side effect in some patients.", "population_specificity": "Transplant-eligible patients with newly diagnosed multiple myeloma.", "effective_dosage": "Not applicable (study does not focus on Alanine).", "study_duration": "Not applicable (study does not focus on Alanine).", "interactions": "None mentioned (study does not focus on Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:54.899502+00:00"}
{"study_id": 102358, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and tolerability of GLE/PIB when coadministered with an oral contraceptive containing low-dose ethinyl oestradiol, focusing on potential alanine aminotransferase (ALT) elevation.", "results_summary": "The study found no confirmed Grade \u22652 ALT elevation or drug-induced liver injury when GLE/PIB was coadministered with low-dose EE/levonorgestrel. Adverse events were minimal, and drug concentrations remained within expected ranges.", "population_specificity": "Healthy premenopausal women.", "effective_dosage": "GLE/PIB (300/120 mg) and EE/levonorgestrel (20/100 \u03bcg).", "study_duration": "4 cycles (Cycles 1-2: EE/levonorgestrel alone; Cycles 3-4: coadministration with GLE/PIB).", "interactions": "None mentioned beyond the coadministration with oral contraceptives.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.450991+00:00"}
{"study_id": 102362, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to investigate changes in plasma alanine levels in transgender women undergoing feminizing gender-affirming hormone therapy (GAHT) with different anti-androgens.", "results_summary": "The study found a cyproterone acetate-specific decrease in alanine levels, suggesting a potential metabolic shift toward an adult female profile. No adverse effects or safety concerns related to alanine were reported.", "population_specificity": "Transgender women (n = 53) receiving feminizing GAHT, randomized to cyproterone acetate or spironolactone.", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:00.068734+00:00"}
{"study_id": 102361, "supplement_id": 863, "safety_score": "80", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the long-term (3-year) efficacy and safety of valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, including monitoring alanine aminotransferase elevations as a common adverse event.", "results_summary": "The study found that valoctocogene roxaparvovec maintained hemostatic efficacy with a significant reduction in annualized bleeding rates and FVIII utilization, while mild alanine aminotransferase elevations remained the most common adverse event. Clinically meaningful improvements in quality of life were also observed.", "population_specificity": "134 adult males with severe hemophilia A who were receiving FVIII prophylaxis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "3 years (156 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:00.911040+00:00"}
{"study_id": 102359, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, and preliminary efficacy of ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A, in patients with advanced solid tumors.", "results_summary": "The study found that ivonescimab had manageable safety profiles, with common adverse events including rash, arthralgia, and hypertension. It showed promising efficacy signals, with a 25.5% objective response rate and 63.8% disease control rate in evaluable patients.", "population_specificity": "Patients with advanced solid tumors, including platinum-resistant ovarian cancer, pMMR colorectal cancer, non-small cell lung cancer, and endometrial cancer.", "effective_dosage": "0.3, 1, 3, 10, 20, or 30 mg/kg intravenously every 2 weeks; MTD was 20 mg/kg.", "study_duration": "From October 2, 2019, to January 14, 2021 (exact duration per patient not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:00.931630+00:00"}
{"study_id": 102364, "supplement_id": 863, "safety_score": "75", "efficacy_score": null, "quality_score": 80, "study_goal": "The researchers aimed to investigate the causes and implications of hepatocellular injury, marked by elevated alanine aminotransferases (ALT), following gene therapy for haemophilia.", "results_summary": "The study found that hepatocellular injury, characterized by ALT elevations, is typically transient and asymptomatic, with no evidence of drug-induced liver injury (DILI). Liver biopsies showed sinusoidal infiltration without significant inflammation.", "population_specificity": "Patients with haemophilia undergoing gene therapy using adeno-associated virus (AAV) vectors.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:02.034751+00:00"}
{"study_id": 102363, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were investigating the anti-tumor activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma, not specifically Alanine.", "results_summary": "The study found that cabozantinib showed promising efficacy in advanced adrenocortical carcinoma, with 72.2% of patients achieving progression-free survival at 4 months. Adverse events included elevated alanine aminotransferase concentrations in 11% of patients, but no treatment-related deaths occurred.", "population_specificity": "Adult patients (aged \u226518 years) with advanced adrenocortical carcinoma, not candidates for surgery with curative intent.", "effective_dosage": "Oral cabozantinib 60 mg daily, with optional dose reduction for adverse events.", "study_duration": "Median follow-up was 36.8 months (IQR 30.2-50.3).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.061217+00:00"}
{"study_id": 102365, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were assessing the safety and efficacy of parsaclisib in combination with standard of care treatments for relapsed/refractory B-cell lymphoma, not specifically evaluating Alanine.", "results_summary": "The study reported increased alanine aminotransferase levels in 37.5% of patients receiving Treatment C (parsaclisib plus ibrutinib), but did not evaluate Alanine's effects or safety.", "population_specificity": "50 patients with relapsed/refractory B-cell lymphoma.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:04.545204+00:00"}
{"study_id": 102366, "supplement_id": 863, "safety_score": "70", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety, tolerability, and pharmacokinetics of pyronaridine (PYR) and piperaquine (PQP) combinations, including their effects on alanine aminotransferase levels.", "results_summary": "The study found that PYR-containing regimens led to asymptomatic transient increases in alanine aminotransferase in some participants, but no serious adverse events or study withdrawals occurred. Liver enzyme elevations were consistent with known safety profiles of related antimalarials.", "population_specificity": "Healthy adult males or females of Black sub-Saharan African ancestry.", "effective_dosage": "Registered dose for uncomplicated malaria, administered orally once daily for 3 days.", "study_duration": "3 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:08.604611+00:00"}
{"study_id": 102360, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy of individualized homeopathic medicinal products (HMPs) in preventing the progression from pre-diabetes to diabetes, with secondary outcomes including liver enzyme levels (alanine transaminase).", "results_summary": "The study found that HMPs significantly reduced the progression from pre-diabetes to diabetes compared to placebo, with notable improvements in HbA1C%, OGTT, and serum ALT (alanine transaminase) levels. Secondary outcomes, including liver enzymes, also showed significant improvements in the verum group.", "population_specificity": "Sixty participants with pre-diabetes in Kolkata, India.", "effective_dosage": "Not specified", "study_duration": "Six months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:08.940333+00:00"}
{"study_id": 102367, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated the clinical and laboratory aspects of dengue patients, including elevated hepatic enzymes such as alanine aminotransferase, but did not specifically study alanine as a supplement.", "results_summary": "The study found elevated alanine aminotransferase levels in nearly half of the dengue patients, indicating liver involvement, but did not assess alanine as a therapeutic or dietary supplement.", "population_specificity": "450 confirmed dengue patients in Bangladesh during the 2023 outbreak, predominantly young adults (mean age 33 years) with a nearly equal male-to-female ratio.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:10.315115+00:00"}
{"study_id": 102368, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to assess the hepatic safety profile of bimekizumab in patients with psoriasis, focusing on liver function abnormalities and adverse events related to alanine aminotransferase (ALT) and aspartate aminotransferase (AST).", "results_summary": "Over 2 years, hepatic adverse events with bimekizumab were consistent, and rates of ALT/AST elevations were similar to comparators (placebo, adalimumab, secukinumab, ustekinumab). Liver fibrosis markers (FIB-4, APRI) did not worsen.", "population_specificity": "Patients with psoriasis (n=2186).", "effective_dosage": "Not specified in the abstract.", "study_duration": "2 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:10.757312+00:00"}
{"study_id": 102370, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and efficacy of Ivacaftor (IVA) in infants aged 1 to <4 months with cystic fibrosis (CF) and CFTR variants.", "results_summary": "IVA dosing in infants achieved exposures previously shown to be safe and efficacious, with improvements in CFTR function, pancreatic function, intestinal inflammation, and growth parameters. However, one infant discontinued due to elevated alanine aminotransferase.", "population_specificity": "Infants aged 1 to <4 months with CF and IVA-responsive CFTR variants.", "effective_dosage": "Initial low dose based on age and weight, adjusted at day 15 based on PK measurements.", "study_duration": "Through week 24.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:11.868754+00:00"}
{"study_id": 102371, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of low/moderate-intensity statin combined with ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (ASCVD).", "results_summary": "The study found no significant changes in alanine aminotransferase (ALT) levels, indicating no adverse effects on liver function related to the treatments. A significant difference was observed only in creatine phosphokinase (CK) levels.", "population_specificity": "Patients with atherosclerotic cardiovascular disease (ASCVD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:11.979841+00:00"}
{"study_id": 102369, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether a finite 48-week treatment regimen involving JNJ-3989, JNJ-6379, and NA could achieve functional cure in NA-suppressed HBeAg-negative CHB patients, with a focus on HBsAg reduction and clinical outcomes.", "results_summary": "The study found no functional cure (HBsAg seroclearance) in any patient, but the active treatment arm showed pronounced HBsAg reduction, fewer post-treatment HBV DNA increases, and fewer alanine aminotransferase flares compared to the control arm.", "population_specificity": "Nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B.", "effective_dosage": "JNJ-3989 (200 mg subcutaneously every 4 weeks) + JNJ-6379 (250 mg oral daily) + NA (oral daily).", "study_duration": "48 weeks of treatment followed by 48 weeks off-treatment follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:13.661414+00:00"}
{"study_id": 102372, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of gender-affirming hormone therapy (GAHT) on laboratory measurements, including alanine transaminase, in transgender and gender-diverse adolescents.", "results_summary": "The study found no significant differences in alanine transaminase levels in adolescents receiving GAHT, suggesting stability in liver function markers. Abnormal results were rare and transient if present.", "population_specificity": "Transgender and gender-diverse adolescents (68% designated female at birth) with no prior gonadotropin-releasing hormone analog use.", "effective_dosage": "Not specified", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:18.177853+00:00"}
{"study_id": 102373, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the safety and effectiveness of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) in treating large hepatic hemangiomas (LHH), not specifically to evaluate Alanine.", "results_summary": "The study found that RFA was significantly more effective than TACE for treating LHH, with higher postoperative efficacy rates (82.1% vs. 55.8%) but longer operating times and higher costs. Alanine aminotransferase levels were measured postoperatively but were not the primary focus of the study.", "population_specificity": "82 patients with large hepatic hemangiomas (5-9.9 cm in diameter) treated at Chaoyang Central Hospital.", "effective_dosage": "Not available", "study_duration": "Postoperative follow-up at 6-12 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:20.493237+00:00"}
{"study_id": 102375, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and feasibility of combining LOAd703 (an oncolytic adenovirus) with chemotherapy for advanced pancreatic ductal adenocarcinoma, not specifically focusing on Alanine.", "results_summary": "The study found that combining LOAd703 with nab-paclitaxel plus gemcitabine was feasible and safe, with common adverse events including elevated liver enzymes (alanine aminotransferase in 24% of patients). Alanine itself was not the primary focus of the study.", "population_specificity": "Patients 18 years or older with unresectable or metastatic pancreatic ductal adenocarcinoma.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up time was 6 months (IQR 4-10).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:21.455991+00:00"}
{"study_id": 102376, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether switching from a triple antiretroviral therapy (3DR) to a two-drug regimen (2DR) containing dolutegravir plus lamivudine affected specific biological pathways, including changes in alanine levels.", "results_summary": "The study found that switching to 2DR led to an up-regulation of alanine and other molecules, potentially linked to inflammation, immune pathways, and lipid/glucose metabolism, though the clinical significance remains uncertain.", "population_specificity": "Virologically suppressed persons with HIV.", "effective_dosage": "Not specified.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:22.151756+00:00"}
{"study_id": 102374, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety, feasibility, and metabolic outcomes of bariatric surgery (specifically sleeve gastrectomy) in post-liver transplantation patients, including its effects on alanine transaminase levels.", "results_summary": "The study found significant and sustained weight loss post-bariatric surgery, with notable reductions in alanine transaminase levels (40.5\u00b128.5 U/L to 27.1\u00b125.1 U/L post-BS, p=0.05) and HbA1c levels. Sleeve gastrectomy was shown to be safe and feasible with favorable metabolic consequences, including resolution of metabolic dysfunction-associated steatotic liver disease.", "population_specificity": "Post-liver transplantation patients who underwent bariatric surgery (n=25) compared to non-bariatric surgery liver transplantation patients (n=187).", "effective_dosage": "Not applicable (surgical intervention).", "study_duration": "Follow-up periods included 1-3 years and 3-5 years post-bariatric surgery.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:22.567283+00:00"}
{"study_id": 102378, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy and safety of probiotic preparations in improving liver function, specifically by reducing alanine aminotransferase levels, in patients with alcoholic liver disease.", "results_summary": "The meta-analysis found that probiotic preparations significantly improved liver function in patients with alcoholic liver disease, notably reducing alanine aminotransferase levels. The results suggest probiotics may also reduce inflammatory responses and regulate intestinal flora.", "population_specificity": "Patients with alcoholic liver disease.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:23.314280+00:00"}
{"study_id": 102377, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers investigated whether empagliflozin reduces hepatic steatosis in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus, with secondary outcomes including changes in alanine aminotransferase levels.", "results_summary": "The study found no significant difference in alanine aminotransferase drop \u2265 17 U/L between the empagliflozin and placebo groups (16.3% vs. 12.2%; p = 0.564). Empagliflozin showed a greater reduction in hepatic fat content but no significant impact on alanine aminotransferase-related outcomes.", "population_specificity": "Adults with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus (fasting plasma glucose < 7 mmol/L and HbA1c < 6.5%).", "effective_dosage": "Empagliflozin 10 mg daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:24.569046+00:00"}
{"study_id": 102379, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the beneficial effects and applicability of remote ischemic preconditioning (RIPC) in hepatectomy, focusing on its impact on liver injury markers like alanine transaminase (ALT).", "results_summary": "RIPC showed short-term liver protective effects, with lower ALT levels on postoperative days 1 and 3 compared to controls, but heterogeneity and insufficient evidence limit conclusions on routine clinical use.", "population_specificity": "Patients undergoing hepatectomies (865 participants across 10 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:26.336436+00:00"}
{"study_id": 102351, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the risk of laboratory abnormalities in acne patients treated with isotretinoin versus oral antibiotics, including effects on alanine transaminase (ALT) levels.", "results_summary": "The study found no significant risk of grade \u22653 impairment in alanine transaminase (ALT) levels in patients treated with isotretinoin. Most laboratory abnormalities occurred 1-3 months after treatment initiation.", "population_specificity": "Patients with acne prescribed isotretinoin (n=79,012) or oral antibiotics (n=79,012).", "effective_dosage": "Not specified", "study_duration": "Initial 3 months of treatment, with follow-up for abnormalities documented 1-3 months after initiation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:28.480820+00:00"}
{"study_id": 102383, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the effects of lifestyle interventions, including diet, exercise, and dietary supplements, on pediatric MASLD, with a mention of alanine aminotransferase as a surrogate marker.", "results_summary": "The study found that lifestyle interventions, particularly a combination of diet and exercise, improved surrogate markers of MASLD, such as serum alanine aminotransferase and hepatic fat fraction. However, direct research on alanine's specific effects was not highlighted.", "population_specificity": "Children and adolescents with obesity and MASLD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:30.074758+00:00"}
{"study_id": 102381, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to identify predictors of treatment outcomes, including the role of alanine aminotransferase (ALT) normalization, in people with autoimmune hepatitis (AIH).", "results_summary": "ALT normalization occurred in 63.8% of patients by 12 months, with older age and female sex associated with higher chances of normalization. Sustained elevated aminotransferase levels, but not IgG, were linked to poorer long-term outcomes.", "population_specificity": "691 patients with AIH (median age 49, 75.4% female) across 11 Canadian centers.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 6 years (25th-75th percentile, 2.5-11 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:30.338701+00:00"}
{"study_id": 102384, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if alanine, as part of a metabolic risk score (MRS), could improve mortality risk stratification in heart failure patients.", "results_summary": "Alanine was included in the MRS, which was associated with a significantly increased rate of death (hazard ratio, 2.2) and improved risk stratification beyond established clinical markers. The study did not isolate alanine's individual effects.", "population_specificity": "1382 heart failure patients (median age 78, 52% men, 43% with reduced ejection fraction).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:30.645202+00:00"}
{"study_id": 102380, "supplement_id": 863, "safety_score": "60", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and tolerability of epacadostat plus pembrolizumab and chemotherapy in Japanese patients with advanced NSCLC, including monitoring alanine aminotransferase levels as part of safety assessments.", "results_summary": "The study found that the combination therapy was tolerable, with 29% of patients experiencing dose-limiting toxicities, including increased alanine aminotransferase (grade 2 or 3). All patients had treatment-related adverse events, and the objective response rate was 47%.", "population_specificity": "Japanese patients aged \u226520 years with advanced non-small-cell lung cancer (NSCLC), stage IIIB or IV, and no prior systemic therapy.", "effective_dosage": "Epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every 3 weeks, plus chemotherapy (cisplatin/carboplatin with pemetrexed or paclitaxel).", "study_duration": "Up to 35 cycles (approximately 2 years) for pembrolizumab, with 4 cycles of chemotherapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:31.048549+00:00"}
{"study_id": 102385, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the safety and immunogenicity of HIV vaccine regimens using different adjuvants (alum, MF59, or no adjuvant), including evaluating the occurrence of alanine aminotransferase increases as a safety measure.", "results_summary": "The study found that increased alanine aminotransferase was the most frequent related adverse event, occurring in 1.5% of participants (1 severe, 1 mild), but overall vaccinations were safe and well-tolerated. No significant differences in immune responses were observed between the adjuvant groups.", "population_specificity": "132 healthy adults without HIV in South Africa, Zimbabwe, and Mozambique.", "effective_dosage": "Not specified for alanine (adjuvant-related effects were the focus).", "study_duration": "The intervention lasted from month 0 to month 12, with follow-up at month 6.5.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:33.376753+00:00"}
{"study_id": 102389, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of febuxostat and benzbromarone in treating hyperuricemia and gout, focusing on their effects on serum uric acid levels and liver/kidney function.", "results_summary": "Benzbromarone was more effective in rapidly reducing serum uric acid levels and inhibiting inflammation, while febuxostat showed comparable long-term effects on liver and kidney function.", "population_specificity": "Hyperuricemia and gout patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:36.494513+00:00"}
{"study_id": 102388, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a pH-sensitive nanocarrier (BPM-PD@PTX) for delivering paclitaxel to NSCLC brain metastases, including its impact on alanine aminotransferase (ALT) levels.", "results_summary": "BPM-PD@PTX reduced adverse reactions (over 83.7%) in ALT and AST levels compared to nab-PTX, while improving therapeutic efficacy with a smaller tumor area (14.6%) and extended survival. The nanocarrier also increased the maximum tolerated dose of PTX from 25 mg/kg to 45 mg/kg.", "population_specificity": "Patients with non-small cell lung cancer (NSCLC) brain metastases.", "effective_dosage": "Maximum tolerated dose increased to 45 mg/kg (PTX equivalent).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:36.670704+00:00"}
{"study_id": 102391, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of an alanine-threonine polymorphism in the EPIYA-B motif of CagA in modifying cancer risk through inflammatory responses and host cell polarity.", "results_summary": "The study found that an alanine-threonine polymorphism in the EPIYA-B motif of CagA affects cancer risk by altering inflammatory responses and disrupting host cell polarity. Additionally, other SNPs in H. pylori were identified as potentially increasing gastric cancer risk.", "population_specificity": "Human gastric epithelial cells infected with Helicobacter pylori.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:38.434687+00:00"}
{"study_id": 102393, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the impact of silymarin (SIL) supplementation on hepatic, renal, and oxidative stress markers, including alanine transaminase (ALT).", "results_summary": "SIL supplementation significantly reduced serum levels of ALT and other liver markers, with potential hepatoprotective effects, especially with long-term and high-dose use. No significant nephroprotective effects or impact on oxidative stress markers were observed.", "population_specificity": "Participants in randomized controlled trials (RCTs), including those with liver disease.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Trials with durations \u226512 weeks showed more pronounced effects.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:39.228633+00:00"}
{"study_id": 102390, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether teduglutide treatment could improve liver chemistries, including alanine aminotransferase levels, in patients with short bowel syndrome-associated intestinal failure (SBS-IF).", "results_summary": "Teduglutide treatment significantly reduced alanine aminotransferase levels (-12.15 IU/L) and other liver chemistry markers compared to placebo, independent of reductions in parenteral nutrition dependence. These improvements suggest potential benefits for liver health in SBS-IF patients.", "population_specificity": "Adult patients with SBS-IF and parenteral nutrition/intravenous fluid dependence but without baseline liver disease.", "effective_dosage": "0.05 or 0.10 mg/kg/day, administered subcutaneously once daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:39.619532+00:00"}
{"study_id": 102386, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the ability of multiparametric US with ATI and 2D SWE for predicting metabolic dysfunction-associated steatohepatitis (MASH) in participants with MAFLD.", "results_summary": "The study found that attenuation coefficient (AC) was a significant predictor of MASH, with an odds ratio of 3.32. The diagnostic performance was evaluated using AUC analysis in training and validation groups.", "population_specificity": "Adults with MAFLD, including those with hepatitis B virus infection, from 12 tertiary hospitals in China.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:40.520494+00:00"}
{"study_id": 102392, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the off-label use of bulevirtide (an HDV entry inhibitor) in patients with decompensated HDV cirrhosis, focusing on virologic and biochemical responses, as well as clinical improvements.", "results_summary": "The study found that 74% of patients achieved virologic response and normal alanine aminotransferase levels, with 47% showing clinical improvement from Child-Pugh B to A. Adverse events included self-limited alanine aminotransferase flares and increased bile acids, but these were not considered treatment-related.", "population_specificity": "Patients with HDV and decompensated liver cirrhosis (Child-Pugh B), median MELD score of 12, from German, Austrian, and Italian centers (n=19, 47% male, mean age 51 years).", "effective_dosage": "Not specified", "study_duration": "Median observation period of 41 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:41.027085+00:00"}
{"study_id": 102394, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the safety and tolerability of durvalumab combined with concurrent chemoradiotherapy (cCRT) in patients with unresectable, stage III non-small-cell lung cancer (NSCLC), not specifically Alanine.", "results_summary": "The study found that durvalumab combined with cCRT was well tolerated with a manageable safety profile and showed encouraging antitumor activity in NSCLC patients. One patient experienced dose-limiting toxicity (grade 4 alanine aminotransferase increase), but no other significant safety concerns were noted.", "population_specificity": "Patients with previously untreated, unresectable, stage III NSCLC.", "effective_dosage": "Durvalumab every 4 weeks (Q4W) with varying chemotherapy regimens (cisplatin + etoposide, carboplatin + paclitaxel, or carboplatin/cisplatin + pemetrexed) and radiotherapy.", "study_duration": "Until disease progression or unacceptable toxicity (median follow-up not specified in the abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:43.001324+00:00"}
{"study_id": 102396, "supplement_id": 863, "safety_score": "65", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant therapy in early-stage hormone receptor-positive, HER2-negative breast cancer, including monitoring alanine aminotransferase elevation as an adverse event.", "results_summary": "The study found that tucidinostat plus exemestane showed promising clinical responses, including Ki67 suppression and radiologic objective response, but had a low rate of PEPI score 0. Adverse events included alanine aminotransferase elevation among others.", "population_specificity": "Patients with stage II-III hormone receptor-positive, HER2-negative breast cancer.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:44.984844+00:00"}
{"study_id": 102397, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare clinical and laboratory features of non-A-E hepatitis (NAEH) with acute viral hepatitis (AVH) and autoimmune hepatitis (AIH), including histopathology, to determine the etiology and course of NAEH.", "results_summary": "The study found that NAEH had similar features to viral hepatitis, with jaundice as the most common presentation, and concluded that NAEH is likely viral in origin and self-limiting without specific treatment.", "population_specificity": "Patients with hepatocellular jaundice, including 15 with NAEH, 25 with acute AIH, and 45 with AVH.", "effective_dosage": "Not available", "study_duration": "Follow-up at three months for NAEH and AIH.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:44.988447+00:00"}
{"study_id": 102399, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to understand the relationship between gut microbiome changes, including alterations in alanine levels, and ME/CFS.", "results_summary": "The study found a significant reduction in microbial metabolites, including alanine, in ME/CFS patients compared to healthy controls, suggesting a potential link between alanine levels and the disorder.", "population_specificity": "553 ME/CFS patients and 480 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:45.849519+00:00"}
{"study_id": 102400, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to assess the efficacy and safety of berberine in treating non-alcoholic fatty liver disease (NAFLD), focusing on liver function markers, lipid profiles, and insulin sensitivity.", "results_summary": "Berberine significantly improved liver enzymes (ALT, AST, GGT), lipid profiles (TC, TG, LDL-C), insulin sensitivity (HOMA-IR), and BMI in NAFLD patients, with only mild gastrointestinal adverse events reported.", "population_specificity": "811 patients with NAFLD across 10 randomized controlled trials.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:47.749782+00:00"}
{"study_id": 102401, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of soy isoflavone supplementation on serum alanine aminotransferase (ALT) levels and other markers in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Soy isoflavone intake significantly decreased ALT, AST, CAP score, and steatosis grade while increasing fetuin A levels, but did not affect fibrosis grade, GGT, or FGF-21 levels. Placebo showed a significant decline in GGT but no other notable changes.", "population_specificity": "50 patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "100 mg/day (two tablets).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:48.652223+00:00"}
{"study_id": 102398, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the long-term (24-month) efficacy and safety of etranacogene dezaparvovec, a gene therapy for haemophilia B, including its impact on alanine aminotransferase levels.", "results_summary": "The study found that etranacogene dezaparvovec significantly reduced bleeding rates and maintained stable factor IX activity, with 96% of participants remaining free of factor IX prophylaxis at 24 months. An increase in alanine aminotransferase was reported in 17% of participants, but no serious treatment-related adverse events or deaths occurred.", "population_specificity": "Adult males aged 18+ with severe or moderately severe haemophilia B and a severe bleeding phenotype.", "effective_dosage": "Single intravenous infusion of etranacogene dezaparvovec (2 \u00d7 10^13 gc/kg).", "study_duration": "Median follow-up of 26.51 months post-infusion.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:49.056934+00:00"}
{"study_id": 102403, "supplement_id": 863, "safety_score": "60", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of glesatinib, an oral inhibitor of MET and AXL, in patients with advanced, previously treated NSCLC with MET activating alterations.", "results_summary": "Glesatinib showed modest clinical activity with an overall ORR of 11.8%, and higher response rates in specific subgroups (e.g., 25.0% in ctDNA-tested MET mutations). Common adverse events included diarrhea, nausea, and increased alanine aminotransferase.", "population_specificity": "Patients with advanced, previously treated non-small cell lung cancer (NSCLC) with MET activating mutations or amplification.", "effective_dosage": "1050 mg BID (FBS capsule) or 750 mg BID (SDD tablet).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:49.705600+00:00"}
{"study_id": 102405, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of activated charcoal in interrupting the enterohepatic circulation to treat amatoxin poisoning, not specifically Alanine.", "results_summary": "Activated charcoal was associated with improved survival (75% in control vs. higher in treated groups) and reduced markers of liver function, but not liver injury markers.", "population_specificity": "Patients with amatoxin poisoning.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:51.237189+00:00"}
{"study_id": 102408, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare patient outcomes (specifically time to ALT normalization and mortality) between inpatient and outpatient settings for severe immune checkpoint inhibitor (ICI) hepatitis.", "results_summary": "Hospitalization was not associated with faster ALT normalization or reduced mortality in patients with high-grade ICI hepatitis. The study also suggested that Common Terminology Criteria for Adverse Events may overestimate liver injury severity.", "population_specificity": "294 ICI-treated patients with grade 3-4 ICI hepatitis, including a subgroup of 152 melanoma patients.", "effective_dosage": "Not specified", "study_duration": "Median hospitalization duration was 6 days (IQR 3-11).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:53.237960+00:00"}
{"study_id": 102406, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify clinical characteristics and risk factors for severe COVID-19 in gynecological cancer patients undergoing chemotherapy, with a focus on biochemical indices including alanine transaminase (ALT).", "results_summary": "The study found that plasma levels of ALT decreased in SARS-CoV-2-infected chemotherapy patients, with more pronounced changes in relapsed patients and those with COVID-19 within 2 weeks after chemotherapy. Higher baseline ALT was associated with severe COVID-19.", "population_specificity": "Gynecological cancer patients undergoing chemotherapy, both SARS-CoV-2-infected and non-infected.", "effective_dosage": "Not available", "study_duration": "Observational period from August 1, 2022, to January 31, 2023.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:54.101684+00:00"}
{"study_id": 102409, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of raltitrexed intraperitoneal perfusion during radical surgery for elderly colorectal cancer patients, including its impact on alanine transaminase levels.", "results_summary": "The study found that raltitrexed perfusion did not significantly increase postoperative complications or side effects compared to saline, though alanine transaminase levels were temporarily elevated one day after surgery. The treatment also significantly reduced the positive rate of carcinoembryonic antigen mRNA in peritoneal lavage fluid.", "population_specificity": "Elderly patients with colorectal cancer undergoing radical surgery.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Intervention occurred during surgery, with follow-up measurements on the first and third postoperative days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:54.729521+00:00"}
{"study_id": 102410, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of pemafibrate on serum biochemical parameters, including alanine aminotransferase (ALT), in male patients with coronary artery disease and metabolic syndrome (MetS).", "results_summary": "Pemafibrate significantly reduced serum triglyceride levels and improved liver function markers, including a notable decrease in alanine aminotransferase (ALT) levels (-25.1% in the MetS group). The drug also improved insulin resistance in the MetS group.", "population_specificity": "Male patients with coronary artery disease and metabolic syndrome (MetS) or without MetS.", "effective_dosage": "Not specified", "study_duration": "24 weeks per treatment phase (crossover design)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:56.594928+00:00"}
{"study_id": 102411, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study evaluated the efficacy and safety of camrelizumab plus famitinib as a first-line treatment for advanced or metastatic NSCLC patients with PD-L1 TPS \u22651%, not specifically focused on Alanine.", "results_summary": "The study found increased alanine aminotransferase (12.2%) as a common treatment-related adverse event of grade 3 or higher, but did not assess Alanine's effects directly.", "population_specificity": "Advanced or metastatic NSCLC patients with PD-L1 TPS \u22651%.", "effective_dosage": "Not applicable (study did not focus on Alanine dosage).", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:57.014485+00:00"}
{"study_id": 102413, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to identify potential causal relationships between urinary metabolites, including alanine, and allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis.", "results_summary": "Alanine was identified as a urinary metabolite with significant protective effects against allergic rhinitis (OR 0.280; 95% CI: 0.125-0.628; P = 0.002). The study suggests alanine may play a role in reducing the risk of allergic diseases.", "population_specificity": "European (FinnGen biobank) and Asian (Biobank Japan) cohorts.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:57.389022+00:00"}
{"study_id": 102412, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the pharmacokinetics, safety profile, and tolerability of TBN tablets in healthy Chinese volunteers.", "results_summary": "TBN tablets demonstrated a good safety profile and were well tolerated, with steady-state concentrations achieved after 4 days of oral administration. No significant adverse effects were reported.", "population_specificity": "Healthy Chinese volunteers aged 18-45 with a BMI of 19.0-26.0 kg/m\u00b2.", "effective_dosage": "Single doses of 400-1800 mg (SAD) and multiple doses of 600-1800 mg twice daily for 7 days (MAD).", "study_duration": "7 days for MAD portion.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:58.125935+00:00"}
{"study_id": 102414, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy of shorter (24-week) vs. longer (48-week) tenofovir disoproxil fumarate (TDF) prophylaxis in preventing HBV relapse in cancer patients with chronic hepatitis B undergoing chemotherapy, not specifically to evaluate Alanine.", "results_summary": "The study found that Alanine aminotransferase (ALT) levels remained stable throughout the study, but the primary focus was on TDF efficacy, not Alanine's effects.", "population_specificity": "Cancer patients with chronic hepatitis B undergoing chemotherapy in Taiwan.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:59.709077+00:00"}
{"study_id": 102416, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma, not Alanine.", "results_summary": "The study did not investigate Alanine; it focused on cabozantinib, atezolizumab, and sorafenib in hepatocellular carcinoma patients.", "population_specificity": "Patients aged 18+ with previously untreated advanced hepatocellular carcinoma.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:02.355969+00:00"}
{"study_id": 102415, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the upper limit of normal (ULN) alanine aminotransferase (ALT) levels in individuals with and without metabolic diseases.", "results_summary": "The study found ALT ULN levels were 32 U/L in healthy individuals, with variations by sex (36 U/L in males, 28 U/L in females) and metabolic status (40 U/L in overweight/obese, 29 U/L in normal weight; 36 U/L in T2DM, 33 U/L without T2DM). BMI, HDL, and triglycerides correlated with ALT levels.", "population_specificity": "Individuals without known liver disease, including healthy individuals and those with metabolic diseases (overweight/obese, T2DM).", "effective_dosage": "Not available", "study_duration": "Not applicable (meta-analysis of existing studies)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:02.365054+00:00"}
{"study_id": 102417, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to examine the efficacy of Obeticholic acid (OCA) for treating NASH-related fibrosis and its impact on dyslipidemia, including effects on alanine transaminase levels.", "results_summary": "OCA treatment improved alanine transaminase and aspartate aminotransferase levels, reduced fibrosis and steatosis, but elevated total cholesterol and low-density lipoprotein levels. Pruritus incidence increased with higher OCA doses.", "population_specificity": "Patients with nonalcoholic steatohepatitis (NASH) diagnosed via MRI, CT, or histology.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:03.141576+00:00"}
{"study_id": 102418, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of a mobile app-based lifestyle coaching intervention on physiological and psychological health outcomes, including alanine transferase levels, in patients with NAFLD.", "results_summary": "The intervention significantly improved alanine transferase levels (P=.002) within the intervention group, along with other physiological and psychological outcomes, though the between-group differences were not significant for alanine transferase.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD), mean age 48.9 years, 38.2% female.", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:04.413121+00:00"}
{"study_id": 102421, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety and efficacy of tenofovir alafenamide fumarate (TAF) in preventing mother-to-child transmission of HBV, including its effects on alanine aminotransferase (ALT) levels.", "results_summary": "TAF was as effective as other antivirals in reducing HBV transmission and ALT levels, with no adverse effects on infant development or maternal safety markers like blood creatinine or \u03b22-M.", "population_specificity": "Pregnant women with HBV and their infants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:05.905135+00:00"}
{"study_id": 102419, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The study aimed to assess the response of direct-acting antivirals (DAAs) in chronic hepatitis C (CHC) patients and identify factors affecting treatment response, including elevated alanine transaminase levels.", "results_summary": "Elevated alanine transaminase (ALT) levels were significantly associated with treatment failure (P = 0.021), but DAAs overall showed high efficacy with an 88.75% sustained virological response rate.", "population_specificity": "400 adult CHC patients, diagnosed by positive anti-HCV antibody and detectable HCV RNA, including both cirrhotic and non-cirrhotic individuals.", "effective_dosage": "Not specified (treatment followed National Viral Hepatitis Control Programme guidelines).", "study_duration": "Treatment duration varied; viral load was reassessed \u226512 weeks post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:06.922850+00:00"}
{"study_id": 102422, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether D-alanine, present in sake lees, has a renoprotective effect and reduces blood uremic toxins in CKD patients.", "results_summary": "The study did not report specific results for D-alanine's effects, as it is a pilot study with endpoints including plasma D-alanine changes and fecal microbiome alterations.", "population_specificity": "Patients with chronic kidney disease (CKD).", "effective_dosage": "50 g of sake lees per day (D-alanine content not specified).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:07.394874+00:00"}
{"study_id": 102420, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine the safety and efficacy of allopurinol in increasing thioguanine nucleotides (e-TGN) and reducing methyl mercaptopurine (e-MeMP) levels in pediatric ALL patients without prior signs of skewed thiopurine metabolism.", "results_summary": "Allopurinol significantly increased e-TGN levels and reduced e-MeMP levels, leading to a nearly 50% decline in alanine aminotransferase. The treatment was safe, with no severe adverse events reported, and improved the proportion of patients achieving target white blood cell counts.", "population_specificity": "Pediatric acute lymphoblastic leukemia (ALL) patients from Sweden and Finland without previous clinical signs of skewed 6-mercaptopurine metabolism.", "effective_dosage": "50 mg/m\u00b2 of allopurinol added to maintenance therapy.", "study_duration": "12 weeks of allopurinol intervention.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:08.350889+00:00"}
{"study_id": 102425, "supplement_id": 863, "safety_score": "75", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the prevalence, course, associations, and clinical impact of hematological and biochemical abnormalities, including elevated alanine transaminase (ALT), in infants born to women with IBD treated with thiopurines or biologics.", "results_summary": "Elevated ALT was observed in over half of infants up to 6 months of age, with no significant clinical impact. It was associated with maternal inflammation and elevated 6-methylmercaptopurine at delivery.", "population_specificity": "Infants born to women with inflammatory bowel disease (IBD) treated with thiopurines or biologics.", "effective_dosage": "Not specified", "study_duration": "Follow-up up to 2 years of age", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:11.408436+00:00"}
{"study_id": 102424, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of ADG106, an antibody targeting CD137, in patients with advanced malignancies, including its effects on immune modulation.", "results_summary": "The study found that ADG106 had a manageable safety profile, with dose-limiting toxicity occurring in only one patient at the highest dose. It demonstrated preliminary anti-tumor efficacy, with disease control rates of 47.1% for solid tumors and 54.5% for non-Hodgkin's lymphoma, alongside immune modulation effects.", "population_specificity": "62 patients with advanced malignancies (solid tumors and non-Hodgkin's lymphoma).", "effective_dosage": "Up to 10.0 mg/kg (dose-limiting toxicity at this level).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:11.759352+00:00"}
{"study_id": 102423, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the activity and safety of an ATG-free regimen of eltrombopag with cyclosporin A as a potential treatment for severe aplastic anaemia, not specifically focused on Alanine.", "results_summary": "The study found that eltrombopag and cyclosporin had an overall haematological response rate of 46% by month 6, with common adverse events including increased serum bilirubin, nausea, increased alanine aminotransferase concentration, and diarrhoea. No deaths were considered treatment-related.", "population_specificity": "Adult (\u226518 years) patients with severe aplastic anaemia, treatment-naive, with an Eastern Cooperative Oncology Group performance status of less than 2.", "effective_dosage": "Eltrombopag was initiated at 150 mg (100 mg in patients of Asian ethnicity) and cyclosporin at 10 mg/kg per day.", "study_duration": "6 months of treatment with eltrombopag and cyclosporin, with some patients completing a cyclosporin tapering period up to month 24.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:13.574142+00:00"}
{"study_id": 102427, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify key metabolites, including alanine, involved in the pathogenesis of non-small cell lung cancer (NSCLC) and assess their potential as diagnostic biomarkers.", "results_summary": "The study found that alanine levels showed a downward trend in NSCLC patients compared to healthy individuals, suggesting its potential role as a metabolic biomarker for NSCLC. The consistency of this trend across multiple studies supports its relevance in NSCLC pathogenesis.", "population_specificity": "2768 NSCLC patients and 9873 healthy individuals", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:14.650138+00:00"}
{"study_id": 102426, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the safety and immunogenicity of CoronaVac, a COVID-19 vaccine, in healthy volunteers.", "results_summary": "The study found no serious adverse events among participants, with 13.4% experiencing systemic adverse reactions (fatigue and dizziness being most frequent). Some clinical indicators, including creatinine, changed significantly after vaccination.", "population_specificity": "506 healthy volunteers not previously infected with COVID-19 or vaccinated.", "effective_dosage": "Not specified (study focused on vaccine doses, not Alanine).", "study_duration": "Follow-up occurred prior to first dose, prior to second dose, and 8 weeks after the second dose.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:14.769842+00:00"}
{"study_id": 102428, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "To evaluate the effects of intermittent fasting (IF) on anthropometric, liver damage, and lipid profile markers, including alanine aminotransferase activity, in subjects with NAFLD.", "results_summary": "The study found that IF reduced hepatic steatosis and alanine aminotransferase activity in NAFLD patients, with variable effects on other metabolic markers. Body weight and fat mass were consistently reduced, particularly with ADF and 5:2 IF.", "population_specificity": "470 patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified (intermittent fasting protocols varied: TRF, ADF, 5:2 IF).", "study_duration": "Not specified (duration varied across included studies).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:16.614407+00:00"}
{"study_id": 102429, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical efficacy and quality of traditional Chinese medicine combined with Silibinin in treating nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The combined treatment group showed significantly higher total effectiveness and lower levels of ALT, AST, TC, TG, and GGT compared to Silibinin alone, along with reduced TCM syndrome scores.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD), totaling 1335 participants across 16 RCTs.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:16.796297+00:00"}
{"study_id": 102430, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the pharmacokinetics, pharmacodynamics, and safety of obeticholic acid (OCA) in subjects with NASH fibrosis or cirrhosis, not specifically Alanine.", "results_summary": "The study found that OCA treatment led to robust changes in farnesoid X receptor activation markers and marked decreases in alanine transaminase, aspartate transaminase, and gamma-glutamyltransferase, but did not specifically assess Alanine's effects.", "population_specificity": "Subjects with NASH fibrosis (stages F1-F4) or NASH cirrhosis (Child-Pugh-A).", "effective_dosage": "OCA 10 mg or 25 mg daily.", "study_duration": "85 days for Study 747-117, 28 days for Study 747-118.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:18.821829+00:00"}
{"study_id": 102431, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the long-term safety and tolerability of Cenicriviroc (CVC) in patients with NASH and stage 0-4 liver fibrosis.", "results_summary": "The study found that CVC 150 mg once daily was well tolerated, with treatment-related adverse events reported in 16.8% of patients, mostly mild in intensity. No clinically meaningful changes in hepatic function or liver parameters were observed.", "population_specificity": "Patients with NASH and stage 0-4 liver fibrosis who completed the phase 2 CENTAUR study or reached a predefined endpoint in the phase 3 AURORA study.", "effective_dosage": "150 mg once daily", "study_duration": "Median treatment duration of 33.6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:22.218908+00:00"}
{"study_id": 102433, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the combination therapy of pazopanib and durvalumab in metastatic/recurrent soft tissue sarcoma, not specifically Alanine.", "results_summary": "Elevated alanine aminotransferase (ALT) was reported as a grade 3-4 adverse event in 10.6% of participants, but the study did not assess Alanine's effects or efficacy.", "population_specificity": "Patients with metastatic and/or recurrent soft tissue sarcoma.", "effective_dosage": "Not applicable (Alanine was not a study intervention).", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:22.562272+00:00"}
{"study_id": 102434, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to investigate colchicine's efficacy and safety compared with placebo in people with hand osteoarthritis, not Alanine.", "results_summary": "The study found no significant difference in pain relief between colchicine and placebo groups, with colchicine associated with more adverse events. Elevated alanine aminotransferase concentrations were noted in one placebo group patient.", "population_specificity": "Adults with symptomatic hand osteoarthritis and finger pain (mean age 70.9 years, 69% women).", "effective_dosage": "Not applicable (study focused on colchicine, not Alanine).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:22.954560+00:00"}
{"study_id": 102435, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of simplified HCV treatment regimens (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) in eligible patients and develop an algorithm for non-specialist care.", "results_summary": "The study found that 92.8% of patients achieved sustained virological response, with only 1.9% experiencing Grades 2-4 liver function abnormalities (including alanine aminotransferase). Severe abnormalities (Grades 3-4) were rare (0.23%).", "population_specificity": "7,677 HCV-infected patients from the Taiwan Hepatitis C Registry (TACR) meeting EASL/AASLD-IDSA criteria for simplified treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:24.036817+00:00"}
{"study_id": 102437, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a predictive model for in-hospital mortality risk in patients with acute paraquat poisoning, using alanine aminotransferase as one of the independent predictors.", "results_summary": "The study identified alanine aminotransferase as an independent predictor of in-hospital mortality in acute paraquat poisoning patients, but did not evaluate its efficacy or safety as a supplement.", "population_specificity": "724 patients with acute paraquat poisoning.", "effective_dosage": "Not available", "study_duration": "Data collected within 24 hours of admission.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:24.154825+00:00"}
{"study_id": 102436, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of adjuvant sintilimab, a programmed cell death protein 1 inhibitor, in patients with hepatocellular carcinoma (HCC) accompanied by microvascular invasion (MVI).", "results_summary": "Sintilimab significantly prolonged recurrence-free survival (RFS) compared to active surveillance (median RFS, 27.7 versus 15.5 months; hazard ratio 0.534, 95% confidence interval 0.360-0.792; P\u2009=\u20090.002). Elevated alanine aminotransferase levels (5.2%) and anemia (4.1%) were the most common grade 3 or 4 treatment-related adverse events.", "population_specificity": "Patients with hepatocellular carcinoma (HCC) accompanied by microvascular invasion (MVI).", "effective_dosage": "Intravenous injections every 3 weeks for a total of eight cycles.", "study_duration": "Median follow-up of 23.3 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:26.563044+00:00"}
{"study_id": 102439, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness and safety of tacrolimus (TAC) and mycophenolate mofetil (MMF) as second-line treatments for autoimmune hepatitis (AIH), focusing on biochemical response and adverse effects.", "results_summary": "The study is a phase IIIB randomized controlled trial (TAILOR) comparing TAC and MMF in AIH patients who did not achieve complete biochemical response with first-line therapy. Primary and secondary endpoints include CR rates at 6 and 12 months, adverse effects, fibrogenesis, quality of life, and cost-effectiveness.", "population_specificity": "Patients with autoimmune hepatitis (AIH) who did not reach complete biochemical response after at least 6 months of first-line therapy.", "effective_dosage": "TAC (0.07 mg/kg/day initially, adjusted by trough levels) or MMF (max 2000 mg/day).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:28.700997+00:00"}
{"study_id": 102441, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the efficacy of dapagliflozin versus placebo in improving hepatic function and glucose control in patients with type 2 diabetes and non-alcoholic fatty liver disease, focusing on markers like alanine aminotransferase (ALT).", "results_summary": "Dapagliflozin significantly reduced ALT, AST, fasting glucose, and HbA1c levels but showed no significant effect on HOMA-IR. The results suggest dapagliflozin improves hepatic function and glucose control in the studied population.", "population_specificity": "Patients with type 2 diabetes and non-alcoholic fatty liver disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:30.333981+00:00"}
{"study_id": 102432, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine whether high- or low-SVV strategies during liver surgery affected postoperative complications, including ALT levels.", "results_summary": "No differences in postoperative complications were found between low-SVV and high-SVV groups, but the high-SVV group showed lower eGFRs and higher ALT levels post-surgery.", "population_specificity": "74 patients undergoing hepatectomy for liver tumor resection.", "effective_dosage": "Not specified", "study_duration": "Intraoperative (during surgery)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:31.374300+00:00"}
{"study_id": 102442, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the efficacy and safety of subtyping-based therapy in the first-line treatment of triple-negative breast cancer, not specifically focused on Alanine.", "results_summary": "The study found that subtyping-based therapy improved progression-free survival compared to the control group, with increased alanine aminotransferase reported as a treatment-related adverse event in some participants.", "population_specificity": "Females aged 18-70 years with untreated metastatic or recurrent triple-negative breast cancer.", "effective_dosage": "Not specified for Alanine.", "study_duration": "28-day cycles, median follow-up of 22.5 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:31.426553+00:00"}
{"study_id": 102445, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether serum alanine aminotransferase (ALT) levels could predict induction therapy response in adult patients with hemophagocytic lymphohistiocytosis (HLH).", "results_summary": "The study found a correlation between ALT levels and induction therapy response (P < 0.05), suggesting ALT may be a useful predictor. However, the ferritin/platelet ratio was identified as a more robust predictor of response.", "population_specificity": "Adult patients with HLH (269 participants, divided into remission and non-remission groups).", "effective_dosage": "Not specified", "study_duration": "1-4 weeks after induction therapy", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:32.009514+00:00"}
{"study_id": 102443, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and inhibitory activity of sequential therapy with ropeginterferon alfa-2b and nivolumab in patients with HBV-related HCC recurrence post-surgery.", "results_summary": "The study found that sequential combination therapy led to notable HBV suppression or clearance in some patients, with one case of dose-limiting toxicity (grade 3 alanine transaminase increase). No HCC recurrence was observed during the study period.", "population_specificity": "Patients with HBV-related hepatocellular carcinoma (HCC) recurrence who underwent curative surgery.", "effective_dosage": "Ropeginterferon alfa-2b (450 \u00b5g every two weeks for six doses) followed by nivolumab (up to 0.75 mg/kg every two weeks for three doses).", "study_duration": "Approximately 18 weeks (six doses of ropeginterferon alfa-2b over 12 weeks, followed by three doses of nivolumab over 6 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:33.418372+00:00"}
{"study_id": 102446, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of AAV-based gene therapy for hemophilia, including monitoring alanine aminotransferase (ALT) elevation as an outcome.", "results_summary": "The study found that 63% of hemophilia patients had elevated ALT levels after AAV-based gene therapy, but the abstract does not specify the clinical significance of this finding for alanine itself. The therapy reduced bleeding and factor infusion events significantly.", "population_specificity": "Patients diagnosed with hemophilia treated with AAV-mediated gene therapy.", "effective_dosage": "Not specified", "study_duration": "Follow-up included data 2-3 years post-therapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:35.753756+00:00"}
{"study_id": 102448, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the prevention of postoperative symptomatic pulmonary embolism (PE) in gynecologic cancer patients with asymptomatic venous thromboembolism (VTE) using seamless anticoagulant therapy, not specifically focused on Alanine.", "results_summary": "The study found no symptomatic PE within 28 days postoperatively, but reported adverse events including increased alanine transaminase (ALT) in one patient. The focus was on anticoagulant therapy, not Alanine's effects.", "population_specificity": "Gynecologic cancer patients (ovarian, fallopian tube, peritoneal, endometrial, or cervical cancer) with preoperative asymptomatic VTE.", "effective_dosage": "Not mentioned (study focused on anticoagulant therapy, not Alanine).", "study_duration": "28 days postoperatively.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:37.698607+00:00"}
{"study_id": 102449, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of febuxostat and benzbromarone in treating gout, including their effects on uric acid levels, renal function, and hepatotoxicity markers like alanine transaminase (ALT).", "results_summary": "Febuxostat showed better efficacy in reducing uric acid and improving renal function markers (eGFR, Cr, BUN), while benzbromarone had less hepatotoxicity (lower ALT and AST increases). No significant difference was found in blood lipid effects between the two drugs.", "population_specificity": "Patients with gout", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:38.994634+00:00"}
{"study_id": 102444, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential of stapled peptides, including those involving Alanine, to stabilize helical motifs and enhance therapeutic molecule design.", "results_summary": "The abstract highlights the potential of chemically diverse helix-inducing stapled peptides but does not provide specific results regarding Alanine's effects.", "population_specificity": "Not specified", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:40.511395+00:00"}
{"study_id": 102452, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the efficacy of nucleos(t)ide analogue (NA) therapy in suppressing HBV-derived carcinogenesis, including its effects on alanine aminotransferase levels.", "results_summary": "NAs were found to be highly effective in suppressing HBV-DNA and improving alanine aminotransferase levels, but the rate of functional cure (HBsAg loss) was low, and some cases of HCC occurred during or after NA therapy.", "population_specificity": "Patients with chronic hepatitis B virus (HBV) infection, particularly those at risk for hepatocellular carcinoma (HCC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:40.964412+00:00"}
{"study_id": 102450, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To determine the relationship between choroidal thickness (ChT) and liver damage (measured by ALT and AST levels) in simple AIH patients without ocular symptoms after oral prednisone treatment.", "results_summary": "After treatment, ChT significantly increased in all sectors, while ALT and AST levels significantly decreased. The increase in ChT was strongly correlated with the reduction in liver damage markers.", "population_specificity": "35 simple AIH patients (31 females, mean age 45.66 \u00b1 11.62 years) without ocular symptoms.", "effective_dosage": "Not specified (oral prednisone dosage not detailed).", "study_duration": "Mean (SD) of 24 (1.28) weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:41.307371+00:00"}
{"study_id": 102451, "supplement_id": 863, "safety_score": "30", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to assess the impact of vupanorsen (an ANGPTL3 inhibitor) on hepatic fat fraction (HFF) progression, subgroup differences, and correlations with liver enzyme changes.", "results_summary": "Vupanorsen caused dose-dependent increases in HFF (up to 76%) and liver enzymes, with moderate correlations between HFF and ALT/AST elevations. The study suggests liver enzymes are imperfect indicators of hepatic fat accumulation.", "population_specificity": "286 adults with hyperlipidemia (227 analyzed for HFF).", "effective_dosage": "7 dosing regimens (specific amounts not detailed in abstract).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:41.353582+00:00"}
{"study_id": 102453, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare long-term outcomes of maralixibat treatment in Alagille syndrome (ALGS) patients with a natural history cohort to assess its impact on event-free survival.", "results_summary": "The study found that maralixibat significantly improved event-free survival in ALGS patients compared to the natural history cohort, with a hazard ratio of 0.305 (95% CI, 0.189-0.491; p <0.0001). Sensitivity analyses confirmed the robustness of these findings.", "population_specificity": "Patients with Alagille syndrome (ALGS), a rare genetic disorder causing chronic cholestasis and extrahepatic anomalies.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Up to 6 years of treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:42.348516+00:00"}
{"study_id": 102454, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the phenotypic effects of a novel ZMIZ1 variant involving an alanine-rich domain alteration in a patient with NEDDFSA.", "results_summary": "The study identified a non-frameshift deletion in ZMIZ1 affecting the alanine-rich domain, leading to reduced mutant protein expression and potentially contributing to a more complex disease phenotype.", "population_specificity": "A 6-month-old male infant with NEDDFSA and previously unreported genitourinary anomalies.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:43.862564+00:00"}
{"study_id": 102455, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate the relationship between hepatic complications and inflammatory parameters in dengue infection, not specifically Alanine.", "results_summary": "The study found a higher incidence of liver dysfunction in severe dengue patients, with elevated AST levels, but did not specifically address Alanine's effects.", "population_specificity": "Patients (>12 years) diagnosed with dengue infection at a tertiary care center in North India.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:44.718855+00:00"}
{"study_id": 102456, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between gestational SARS-CoV-2 infection and maternal-fetal outcomes in pregnant women, not specifically related to Alanine.", "results_summary": "The study found that mild COVID-19 infection during pregnancy did not have detrimental effects on maternal and neonatal outcomes, though increased risks of fetal distress and cesarean section were noted.", "population_specificity": "Pregnant women in China, including 311 with SARS-CoV-2 infection and 205 uninfected controls.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:46.273584+00:00"}
{"study_id": 102460, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to describe anthropometric, clinical, and biochemical characteristics, complications, and outcomes in paediatric patients with endogenous Cushing syndrome to aid diagnosis and management.", "results_summary": "Elevated alanine transaminase was a common complication (64% of 227 patients), indicating potential liver involvement in paediatric Cushing syndrome. The study did not focus on alanine as a supplement but noted its association with disease complications.", "population_specificity": "Paediatric patients (\u226418 years) with endogenous Cushing syndrome.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.137625+00:00"}
{"study_id": 102457, "supplement_id": 863, "safety_score": "40", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers investigated the relationship between pazopanib exposure and liver toxicity (measured via alanine transaminase elevations) in real-world patients and evaluated management strategies for pazopanib-induced liver toxicity.", "results_summary": "Liver toxicity occurred in 19% of patients, but pazopanib exposure levels were similar in those with or without toxicity. Half of the patients who continued or restarted pazopanib after liver toxicity could safely resume the same dose.", "population_specificity": "Patients treated with pazopanib in a real-world clinical setting.", "effective_dosage": "Not specified (exposure levels averaged 27.7\u201328.1 mg/L).", "study_duration": "Not specified.", "interactions": "Pazopanib (a medication) was the primary interaction studied.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.582268+00:00"}
{"study_id": 102458, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the feasibility, effectiveness, and safety of pancreatic duct stenting in managing acute biliary pancreatitis (ABP) necessitating ERCP, not specifically focused on Alanine.", "results_summary": "The study found no significant differences in complications or mortality between stent and non-stent groups, but the stent group had shorter fasting and hospitalization times. Alanine aminotransferase (ALT) levels showed no significant differences between groups.", "population_specificity": "Patients with acute biliary pancreatitis (ABP) who underwent ERCP at a single hospital.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.642032+00:00"}
{"study_id": 102459, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of mycophenolate mofetil (MMF) versus azathioprine, both combined with prednisolone, in achieving biochemical remission (normalization of alanine aminotransferase and IgG levels) in treatment-naive autoimmune hepatitis (AIH) patients.", "results_summary": "MMF with prednisolone achieved significantly higher biochemical remission rates (56.4% vs. 29.0%) and complete biochemical response rates (72.2% vs. 32.3%) compared to azathioprine with prednisolone at 24 weeks. MMF also demonstrated superior tolerability, with fewer serious adverse events and treatment discontinuations.", "population_specificity": "Treatment-naive patients with autoimmune hepatitis (mean age 57.9 years, 72.9% female).", "effective_dosage": "Not specified for alanine (study focused on MMF and azathioprine dosages).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:52.361852+00:00"}
{"study_id": 106052, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to explore the cerebral uptake of DHA derived from ALA and its potential neuroprotective effects in neurodegenerative diseases.", "results_summary": "The study found that human biosynthesis of DHA from ALA is very low, and reduced cerebral DHA levels are linked to neurodegenerative diseases like Alzheimer's and Parkinson's. It highlighted the potential of targeting the brain with DHA for therapeutic approaches.", "population_specificity": "Patients with neurodegenerative diseases (e.g., Alzheimer's, Parkinson's).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:59.947002+00:00"}
{"study_id": 106059, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether diets enriched with ALA-rich camelina sativa oil (CSO) modulate inflammation-related gene expression in peripheral blood mononuclear cells (PBMCs) and subcutaneous adipose tissue (SAT) in subjects with impaired fasting glucose.", "results_summary": "The study found that CSO decreased IFNG mRNA expression in PBMCs, suggesting anti-inflammatory effects. However, the change in IFNG expression correlated with CSO intake but not with plasma ALA levels, indicating a potential indirect mechanism.", "population_specificity": "Subjects with impaired fasting glucose.", "effective_dosage": "Not specified.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.808543+00:00"}
{"study_id": 106060, "supplement_id": 872, "safety_score": "85", "efficacy_score": 60, "quality_score": 90, "study_goal": "The researchers aimed to assess the effects of increased intake of plant-based omega-3 (ALA) on all-cause mortality, cardiovascular events, adiposity, and lipids.", "results_summary": "The study found that increasing ALA intake probably makes little or no difference to all-cause mortality, cardiovascular mortality, or CHD mortality, but may slightly reduce the risk of cardiovascular events and arrhythmia. Effects on stroke were unclear.", "population_specificity": "Adults at varying cardiovascular risk, mainly in high-income countries.", "effective_dosage": "Not specified", "study_duration": "12 to 72 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.988284+00:00"}
{"study_id": 106057, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of ALA versus EPA+DHA on lipid profiles, inflammatory status, and fatty acid composition in hypercholesterolemic adults.", "results_summary": "ALA supplementation increased PBMCs' ALA composition but did not improve lipid profiles or inflammation status, nor did it increase EPA/DHA levels in PBMCs. EPA+DHA showed significant benefits in reducing triglycerides and inflammation, unlike ALA.", "population_specificity": "Middle-aged to elderly Chinese adults with hypercholesterolemia (n=123).", "effective_dosage": "4.2 g/d and 7.2 g/d ALA.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.994694+00:00"}
{"study_id": 106054, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to create a database of long-term RCTs to assess the effects of increasing ALA, LCn3, omega-6, or total PUFA intake on health outcomes.", "results_summary": "The study compiled a database of 363 RCTs, with 27 trials specifically altering ALA intake, but did not report specific outcomes or efficacy results for ALA in the abstract. The focus was on methodology and data collection rather than direct findings.", "population_specificity": "Not specified in the abstract (general population inferred from RCT inclusion).", "effective_dosage": "Not specified in the abstract.", "study_duration": "\u226524 weeks (6 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:01.124816+00:00"}
{"study_id": 106053, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of omega-3 and omega-6 PUFA supplements, including ALA, on dry eye signs and symptoms.", "results_summary": "The study found mixed evidence for ALA's efficacy in dry eye management, with some potential benefits in tear production and osmolarity but inconsistent symptom relief. The certainty of evidence was generally low to moderate.", "population_specificity": "4,314 adult participants from 13 countries with dry eye of variable severity and etiology.", "effective_dosage": "Not specified for ALA specifically.", "study_duration": "Follow-up ranged from one to 12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:01.126574+00:00"}
{"study_id": 106058, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to explore the impact of hempseed oil (HSO) supplementation, rich in ALA, on serum lipid profiles and red blood cell fatty acid composition in children and adolescents with primary hyperlipidemia.", "results_summary": "HSO supplementation significantly improved RBC phospholipid composition and omega-3 index but did not affect the serum lipid profile. Total n-3 and n-6 PUFAs increased, while saturated and monounsaturated FAs decreased.", "population_specificity": "Children and adolescents (6-16 years) with primary hyperlipidemia.", "effective_dosage": "3 g/day of HSO, providing 0.7 g/day of ALA.", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:01.544801+00:00"}
{"study_id": 106056, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the signs, symptoms, diagnosis, prevention, and treatment of essential fatty acid deficiency (EFAD), focusing on the roles of linoleic acid (LA) and alpha-linolenic acid (ALA).", "results_summary": "The study found that ALA, as an essential fatty acid, is crucial for preventing EFAD, particularly in patients with conditions limiting fat intake or absorption. Intravenous lipid emulsions (ILEs) containing ALA can prevent EFAD, though early formulations high in LA may promote proinflammatory effects.", "population_specificity": "Patients with conditions severely limiting fat intake, digestion, absorption, or metabolism, particularly those requiring parenteral nutrition.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:01.708890+00:00"}
{"study_id": 106061, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to investigate the antioxidant effects of Alpha-Linolenic Acid (ALA) and its impact on thiol, CAT, SOD, and MDA values in nonstimulated cells.", "results_summary": "The study found that high concentrations of ALA (45 \u03bcg/ml) significantly increased thiol, CAT, and SOD values and reduced MDA values, similar to the effects of dexamethasone.", "population_specificity": "Nonstimulated cells (in vitro study)", "effective_dosage": "45 \u03bcg/ml of ALA", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:07.097989+00:00"}
{"study_id": 106063, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were examining the effects of Alpha-Linolenic Acid (ALA) and other unsaturated fatty acids on cardiometabolic health.", "results_summary": "The abstract does not provide specific results regarding ALA's effects, only mentioning its inclusion in studies on unsaturated fatty acids.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:08.328199+00:00"}
{"study_id": 106065, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the association between fish oil supplementation, particularly ALA, and its benefits for skin health, including anti-inflammatory and wound-healing effects.", "results_summary": "The study found that ALA, along with other PUFAs, has beneficial effects on the skin by reducing inflammation and promoting wound healing, primarily through mechanisms like competing with inflammatory arachidonic acid and inhibiting proinflammatory eicosanoid production.", "population_specificity": "Cell-based, animal-based, and clinical models (no specific human population detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:09.367145+00:00"}
{"study_id": 106062, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the associations of adipose tissue PUFA biomarkers, including ALA, with metabolic syndrome (MetS) in Mesoamerican adults and children.", "results_summary": "Among adults, MetS prevalence was inversely associated with adipose tissue ALA, suggesting a potential protective effect. No significant adverse effects or toxicity related to ALA were reported.", "population_specificity": "468 parents and 201 children aged 7-12 years from Mesoamerican countries (Guatemala, El Salvador, Dominican Republic, Honduras, Nicaragua, Panama, Costa Rica, Belize, and Mexico).", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (no intervention duration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:09.478623+00:00"}
{"study_id": 106070, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the effect of a high-ALA diet on EPA and DHA levels in red blood cells (RBCs) and their oxylipins in plasma among subjects with low EPA and DHA status.", "results_summary": "The study found that a high-ALA diet increased EPA and DHA levels in RBCs and influenced oxylipin levels in plasma, suggesting ALA conversion efficacy.", "population_specificity": "Subjects with low EPA and DHA status.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:10.177225+00:00"}
{"study_id": 106067, "supplement_id": 872, "safety_score": "85", "efficacy_score": 65, "quality_score": 90, "study_goal": "The researchers aimed to assess the effects of increased intake of plant-based omega-3 (ALA) on all-cause mortality, cardiovascular events, adiposity, and lipids.", "results_summary": "The study found that increasing ALA intake probably makes little or no difference to all-cause mortality, cardiovascular mortality, or CHD events, but may slightly reduce the risk of cardiovascular events, CHD mortality, and arrhythmia. Effects on stroke were unclear.", "population_specificity": "Adults at varying cardiovascular risk, mainly in high-income countries.", "effective_dosage": "Not specified", "study_duration": "12 to 72 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:10.240571+00:00"}
{"study_id": 106068, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare the impact of ALA-rich linseed oil on the n-3 HUFA score relative to fish oil supplements and CLA-enriched cheeses.", "results_summary": "The study found that linseed oil intake (4 g/day, containing 2 g ALA) did not significantly impact the n-3 HUFA score, unlike fish oil or CLA-enriched cheeses, which showed dose-dependent improvements.", "population_specificity": "Healthy adults", "effective_dosage": "4 g/day (containing 2 g ALA)", "study_duration": "Not specified for linseed oil (other interventions ranged from 2 weeks to 2 months)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:10.443159+00:00"}
{"study_id": 106069, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to examine the effects of an energy-restricted diet enriched with ALA on fatty acid composition of serum phospholipids in patients with metabolic syndrome.", "results_summary": "The study found that a high-ALA diet (3.4 g/d) did not enrich serum phospholipids with ALA or increase eicosapentaenoic acid levels, nor did it prevent a decrease in docosahexaenoic acid. Both diets similarly reduced various fatty acid concentrations, with no significant intergroup differences except for a higher oleic acid increase in the control group.", "population_specificity": "Overweight or obese patients with features of metabolic syndrome (n=81).", "effective_dosage": "3.4 g/d (high-ALA diet) vs. 0.9 g/d (control diet).", "study_duration": "26 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:12.113887+00:00"}
{"study_id": 106071, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine the effect of plant-derived alpha-linolenic acid (ALA) on plasma FGF23 levels in post-myocardial infarction patients with chronic kidney disease.", "results_summary": "The study found that ALA supplementation (alone or combined with EPA-DHA) was administered, but the abstract does not specify the direct effect of ALA on FGF23 levels, only noting an overall increase in FGF23 levels after 41 months.", "population_specificity": "Post-myocardial infarction patients aged 60-80 years with chronic kidney disease (eGFR < 60 mL/min/1.73 m\u00b2).", "effective_dosage": "1.99 g/day ALA", "study_duration": "41 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:17.130536+00:00"}
{"study_id": 106073, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the ability of ALA to improve endothelial dysfunction in individuals with classic risk factors for atherosclerosis but without diagnosed atherosclerotic disease.", "results_summary": "ALA-enriched diets showed promising results in improving endothelial dysfunction, though EPA+DHA supplementation was more consistently effective. ALA's efficacy was noted in individuals with hyperlipidemia, elevated BMI, metabolic syndrome, or cigarette smoking.", "population_specificity": "Individuals with hyperlipidemia, elevated BMI, metabolic syndrome, or cigarette smoking but no diagnosed atherosclerotic disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.079233+00:00"}
{"study_id": 106072, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to summarize the lipid and cardiometabolic effects of prescription-grade omega-3 fatty acids (n-3FAs), including Alpha-Linolenic Acid (ALA), and evaluate their impact on cardiovascular health and disease.", "results_summary": "The study found that n-3FAs, including ALA, significantly reduce triglycerides, non-HDL cholesterol, and TG-rich lipoprotein cholesterol levels, with notable effects on atherosclerosis risk markers. However, clinical trial evidence supports their use primarily in individuals with established atherosclerotic cardiovascular disease (ASCVD), with inconsistent or lacking data for other cardiometabolic risks like stroke prevention, heart failure, diabetes, and primary prevention.", "population_specificity": "Individuals with established atherosclerotic cardiovascular disease (ASCVD) and other at-risk populations.", "effective_dosage": "High doses (specific amounts not mentioned)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.080819+00:00"}
{"study_id": 106075, "supplement_id": 872, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of increased ALA intake on fatty acid composition in serum phospholipids and erythrocytes, and whether quercetin or sex influenced these outcomes.", "results_summary": "Increased ALA intake significantly raised ALA and EPA levels in serum phospholipids and erythrocytes but did not affect DHA. Quercetin supplementation and sex had no impact on these outcomes.", "population_specificity": "Metabolically healthy men and women (n=67, 34 males and 33 females).", "effective_dosage": "At least 3.3 g/d ALA, with 190 mg/d quercetin or placebo.", "study_duration": "8-week intervention periods separated by an 8-week washout.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.979271+00:00"}
{"study_id": 106076, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to analyze the mineral composition and fatty acid profile in Fabaceae seeds, including the contribution of Alpha-Linolenic Acid (ALA), and assess correlations with phytochemicals and antioxidant activity.", "results_summary": "The study found that lentils had the highest contribution of ALA (13.8 in 100 g) among the tested Fabaceae species. Correlations were noted between total phenols, tannins, and mineral elements, but specific ALA effects were not detailed.", "population_specificity": "Selected Fabaceae species and cultivars (e.g., Andean lupine, lentil).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.986324+00:00"}
{"study_id": 106078, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers sought to revisit the role of omega-3 fatty acids, including ALA, in cardiovascular protection, focusing on their metabolites via cytochrome P450 (CYP450) in hemodynamic modulation.", "results_summary": "The study suggests that omega-3 fatty acids, including ALA, may have a positive effect on blood pressure, though evidence from interventional studies is inconsistent. The biological activity of ALA may depend on its balance with other dietary compounds, particularly omega-6 fatty acids, and genetic polymorphisms.", "population_specificity": "Not specified (general discussion, no specific population studied)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Competing pathways with omega-6 fatty acids mentioned, but no specific drug or supplement interactions noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:19.115999+00:00"}
{"study_id": 106074, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to determine whether diets enriched with Alpha-Linolenic Acid (ALA) improve glycemic control in individuals with or at risk of type 2 diabetes.", "results_summary": "The study found that ALA-enriched diets did not significantly affect HbA1c, fasting blood glucose, or fasting blood insulin levels overall, though subgroup analysis suggested potential dose-dependent reductions in HbA1c and FBG. The results were limited by heterogeneity and a small number of trials.", "population_specificity": "Individuals with or at risk of type 2 diabetes (N = 212 across 8 trials).", "effective_dosage": "Median doses of 4.4 g/day (HbA1c analysis) and 5.4 g/day (FBG/FBI analysis).", "study_duration": "Median duration of 3 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:19.302087+00:00"}
{"study_id": 106079, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the role of ALA in fatty acid profiles, its response to omega-3 supplementation, and its associations with clinical status and treatment response in youth with mood disorders.", "results_summary": "Baseline ALA levels moderated response to omega-3 supplementation, with higher ALA levels predicting better placebo-controlled response. ALA also showed a negative correlation with DHA at baseline.", "population_specificity": "Youth aged 7-14 with mood disorders (depression or bipolar disorder).", "effective_dosage": "2 g omega-3 per day (including 1.4 g EPA, 0.2 g DHA, and 0.27 g other omega-3).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:21.410303+00:00"}
{"study_id": 106080, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Alpha-Linolenic Acid (ALA) affects G0S2 gene expression in obese patients and its role in ALA-induced inhibition of lipolysis.", "results_summary": "ALA significantly reduced plasma triglyceride, free fatty acids, glycerol, IL-6, and TNF-\u03b1 levels while increasing PPAR-\u03b3, G0S2, and GPR120 mRNA expression in PBMC. Decreased plasma FFA levels correlated with increased PPAR-\u03b3 and G0S2 expression, suggesting G0S2 may contribute to ALA's anti-lipolytic effects.", "population_specificity": "Obese patients (n=26)", "effective_dosage": "~4.0 g daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.332855+00:00"}
{"study_id": 106084, "supplement_id": 872, "safety_score": "85", "efficacy_score": 45, "quality_score": 70, "study_goal": "The researchers aimed to systematize findings on whether chia seed (rich in ALA) consumption affects cardiovascular risk factors in humans.", "results_summary": "Most studies showed no significant changes in cardiovascular risk factors, though some reported increases in ALA and EPA levels, reduced post-prandial blood sugar, and isolated improvements in blood pressure or triglycerides. Results were inconsistent and limited by study design.", "population_specificity": "Humans (clinical trials, n = 200 across 7 studies).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Varied (includes acute trials and unspecified durations).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.630439+00:00"}
{"study_id": 106082, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether meeting dietary ALA recommendations (0.7% of total energy) was associated with reduced all-cause and cardiovascular disease mortality in a high cardiovascular risk population with high fish consumption.", "results_summary": "Meeting ALA recommendations was associated with a 28% reduction in all-cause mortality but showed no significant effect on fatal cardiovascular disease. The highest reduction in all-cause mortality occurred in participants meeting both ALA and long-chain n-3 polyunsaturated fatty acid recommendations.", "population_specificity": "High cardiovascular risk participants from Spain with high fish consumption.", "effective_dosage": "0.7% of total energy for ALA; \u2265500 mg/day for long-chain n-3 polyunsaturated fatty acids.", "study_duration": "5.9 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.631739+00:00"}
{"study_id": 106083, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential mechanisms of Alpha-Linolenic Acid (ALA) in providing neuroprotection and neurorestoration against the toxic effects of the nerve agent soman.", "results_summary": "ALA demonstrated pleiotropic properties targeting neuroprotective and neurorestorative pathways, including NF-\u03baB and BDNF, improving cognitive function in soman-exposed animals. The study suggests ALA could be a promising therapy for long-term consequences of nerve agent exposure and other neurodegenerative disorders.", "population_specificity": "Soman-exposed animals (specific species not mentioned).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.736049+00:00"}
{"study_id": 106085, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effect of dietary n-3 PUFAs, including ALA, on skeletal muscle mass and its determinants in hemodialysis patients.", "results_summary": "Patients who achieved the adequate intake (AI) of ALA showed a trend toward higher appendicular skeletal muscle mass (ASM), though the difference was not statistically significant except for ASM (P = 0.047). No significant differences in demographics or nutritional parameters were observed based on ALA intake.", "population_specificity": "111 hemodialysis patients with end-stage renal disease.", "effective_dosage": "Adequate intake (AI) cutoff for ALA was 1.1 g/day for women and 1.6 g/day for men.", "study_duration": "Not specified (cross-sectional study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:27.571954+00:00"}
{"study_id": 106086, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare plasma concentrations of ALA and other fatty acids in subjects with bipolar disorder (BD) versus healthy controls (HCs) and explore correlations with symptom severity and treatment response.", "results_summary": "The study found no statistically significant differences in ALA plasma concentrations between BD and HC groups after correction for multiple comparisons. Exploratory analysis showed altered n-3 PUFA ratios (including DHA:ALA and EPA:ALA) in the BD group after symptomatic recovery.", "population_specificity": "27 symptomatic subjects with bipolar disorder (BD) and 31 healthy controls (HCs).", "effective_dosage": "Not specified", "study_duration": "Observational study with follow-up after symptomatic recovery (duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:28.589725+00:00"}
{"study_id": 106081, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of echium oil (containing ALA and SDA) and linseed oil (containing ALA) on long-chain omega-3 PUFA accumulation in blood and clinical markers.", "results_summary": "Echium oil (EO) increased EPA and DPA levels more effectively than linseed oil (LO) but did not maintain DHA levels. EO also reduced LDL-C and insulin more than LO. Higher BMI negatively affected EPA and DPA increases with EO but not LO.", "population_specificity": "Adults aged 20-69, including subgroups by age (20-35 and 49-69) and BMI (18-25 and >25 kg/m\u00b2).", "effective_dosage": "5 g ALA daily (with 2 g SDA in EO group).", "study_duration": "8 weeks (after a 2-week run-in).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:28.838995+00:00"}
{"study_id": 106087, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of complementary foods with varying ALA and DHA contents on term infant LC-PUFA status.", "results_summary": "Infants receiving ALA-rich rapeseed oil showed higher plasma and RBC levels of ALA and EPA but no difference in DHA levels compared to the control group. The study concluded that rapeseed oil enhances endogenous EPA synthesis but does not affect DHA status.", "population_specificity": "Healthy term infants aged 4 to 10 months.", "effective_dosage": "Small amounts of ALA-rich rapeseed oil (specific dosage not detailed).", "study_duration": "From introduction of complementary feeding (4-6 months) until 10 months of age.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:30.190818+00:00"}
{"study_id": 106091, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the accuracy of a web-based food frequency questionnaire (web-FFQ) in assessing ALA intake compared to its proportion in red blood cell membranes in men with prostate cancer.", "results_summary": "The study found no significant correlation between ALA intake and its proportion in red blood cell membranes (rs=0.130, P=0.332), indicating the web-FFQ was not accurate for assessing ALA intake in this population.", "population_specificity": "Men with prostate cancer (n=60).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:35.097030+00:00"}
{"study_id": 106088, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the evidence regarding omega-3 LCPUFA supplementation, including ALA, for cardiovascular health and determine if higher ALA intake (2g/day) provided benefits over current guidelines (1g/day).", "results_summary": "The study found no evidence to support increasing ALA intake to 2g/day over the current Australian guideline of 1g/day. Omega-3 LCPUFA supplementation showed no clear benefit or harm in primary or secondary prevention of coronary heart disease.", "population_specificity": "General population, including primary and secondary prevention of cardiovascular disease.", "effective_dosage": "1g/day (current guideline), 2g/day (tested but not supported).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:35.153573+00:00"}
{"study_id": 106089, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether \u03c9-3 ALA supplementation improves insulin sensitivity and adiponectin levels in patients with type 2 diabetes mellitus (T2DM).", "results_summary": "ALA supplementation improved insulin sensitivity (M/FFM) and increased adiponectin levels more than placebo, with positive correlations between adiponectin and glucose infusion rate (GIR) and negative correlations with HOMA-IR. The study suggests ALA may enhance glucose homeostasis and metabolic profiles in T2DM patients.", "population_specificity": "Patients with type 2 diabetes mellitus (T2DM).", "effective_dosage": "3 g/d of ALA.", "study_duration": "60 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:35.325700+00:00"}
{"study_id": 106092, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine if baseline levels of ALA and other factors predicted functional improvement in ultra-high-risk (UHR) patients receiving omega-3 PUFA supplementation.", "results_summary": "Higher baseline ALA levels and more severe negative symptoms predicted functional improvement in the omega-3 group, while lower baseline functioning and less severe positive symptoms predicted improvement in the placebo group. Machine learning confirmed baseline fatty acids as predictive of treatment response.", "population_specificity": "Individuals at ultra-high risk (UHR) for psychosis.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:35.333060+00:00"}
{"study_id": 106090, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effect of soyabean oil (ALA-rich) versus sunflower oil on whole-blood PUFA levels in children aged 11-18 years.", "results_summary": "Soyabean oil significantly increased ALA concentrations and improved n-3 and n-6 very-long-chain PUFA levels, while sunflower oil decreased ALA levels. Both oils led to increased beneficial PUFA levels and decreased oleic and palmitic acid levels.", "population_specificity": "Sixty low- and middle-income families with children aged 11-18 years in Bogot\u00e1, Colombia.", "effective_dosage": "One-month supply of cooking oil (specific quantity not stated).", "study_duration": "One month.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:35.513222+00:00"}
{"study_id": 106093, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to clarify the relationship between ALA and breast cancer risk, as well as evaluate its potential anticancer effects compared to other n-3 PUFAs.", "results_summary": "The study found that evidence regarding ALA's role in breast cancer prevention remains equivocal, though it suggests that ALA, like other n-3 PUFAs, may have promising anticancer effects warranting further research.", "population_specificity": "Women (general population, with focus on breast cancer risk).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:36.561634+00:00"}
{"study_id": 106094, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the cardiovascular disease (CVD) benefits of Alpha-Linolenic Acid (ALA) and compare its effects to marine-derived omega-3 PUFAs (EPA + DHA).", "results_summary": "The study found that ALA provides comparable CVD risk reduction benefits to EPA + DHA, though clinical trial evidence for ALA is less extensive. CVD event benefits were reported for ALA, but stronger evidence exists for EPA + DHA due to more controlled study designs.", "population_specificity": "Not specified (general CVD risk population implied).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:37.730802+00:00"}
{"study_id": 106095, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine if echium oil, containing ALA, could reduce weight loss in head and neck cancer patients undergoing radio(chemo)therapy.", "results_summary": "Echium oil increased erythrocyte EPA and GLA levels but did not significantly reduce weight loss or improve nutritional parameters in the studied population.", "population_specificity": "Head and neck cancer patients undergoing radio(chemo)therapy with curative intent.", "effective_dosage": "7.5 ml twice daily (235 mg/ml ALA).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:38.019206+00:00"}
{"study_id": 106098, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the effect of omega-3 fatty acids, including ALA, on zinc transporters and free zinc availability in human neuronal cells, and their significance for neurodegeneration.", "results_summary": "The study suggests a possible link between omega-3 fatty acids (including ALA), zinc transporter levels, and free zinc availability at cellular levels, with implications for neurodegeneration and cellular death. It highlights the importance of these interactions for understanding and treating neurodegenerative diseases.", "population_specificity": "Human neuronal cells and broader implications for vertebrates (based on abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:43.011603+00:00"}
{"study_id": 106097, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effects of foods enriched with vegetable oils, including ALA-rich linseed oil, on cardiovascular risk factors in hypertriglyceridemic subjects.", "results_summary": "The ALA group showed a significant decrease in total cholesterol and LDL cholesterol, and a 38% increase in erythrocyte eicosapentaenoic acid content. Blood lipids were beneficially modified with linseed oil enrichment.", "population_specificity": "Hypertriglyceridemic subjects (triglycerides \u2265 1.5 mmol/L)", "effective_dosage": "7 g ALA/day", "study_duration": "10 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:43.505601+00:00"}
{"study_id": 106102, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential benefits of n-3 PUFAs, including ALA, in reducing pregnancy complications like gestational hypertension, preeclampsia, and gestational diabetes in obese women with metabolic syndrome.", "results_summary": "The study suggests that n-3 PUFAs, including ALA, may lower cardiovascular disease risk and improve vascular function through anti-inflammatory effects, though their efficacy in preventing pregnancy complications in obese women with metabolic syndrome remains unestablished.", "population_specificity": "Pregnant obese women with metabolic syndrome.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:44.641023+00:00"}
{"study_id": 106101, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether supplementation with plant-derived Alpha-Linolenic Acid (ALA), alone or combined with marine EPA-DHA, could reduce NT-proBNP levels, a biomarker of heart failure, in post-myocardial infarction patients.", "results_summary": "The study found that ALA supplementation (2 g/day) did not significantly affect NT-proBNP levels compared to placebo, showing an 8% increase (not statistically significant). Combined EPA-DHA and ALA treatment also showed no significant effect.", "population_specificity": "Post-myocardial infarction patients aged 60-80 years (82% men).", "effective_dosage": "1.98 g/day ALA (provided via margarine).", "study_duration": "40 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:45.055667+00:00"}
{"study_id": 106099, "supplement_id": 872, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine whether a hypoenergetic diet rich in ALA (3.4 g/d) improves biomarkers of systemic inflammation and vascular function compared to a low-ALA diet (0.9 g/d) in overweight-to-obese patients with metabolic syndrome traits.", "results_summary": "Both diets led to significant reductions in inflammatory and vascular biomarkers, but the high-ALA diet showed a more pronounced reduction in YKL-40 compared to the low-ALA diet. No inter-group differences were observed for other biomarkers, though improvements correlated with body fat loss.", "population_specificity": "Overweight-to-obese patients with metabolic syndrome traits (n=81).", "effective_dosage": "3.4 g/d (high-ALA diet) vs. 0.9 g/d (low-ALA diet).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:45.887736+00:00"}
{"study_id": 106103, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of walnuts (rich in ALA) and n-3 FA enriched eggs (rich in DHA and ALA) on cardiovascular disease risk factors in lacto-ovo-vegetarians.", "results_summary": "Walnut consumption increased erythrocyte membrane ALA levels and improved blood lipid profiles (lowered triacylglycerol, total cholesterol, and Apo B) compared to standard eggs, but not n-3 FA enriched eggs. However, walnuts significantly reduced the total:HDL cholesterol ratio compared to both egg treatments.", "population_specificity": "Healthy free-living lacto-ovo-vegetarians", "effective_dosage": "28.4 g of walnuts, 6 times per week", "study_duration": "8 weeks per treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:48.255309+00:00"}
{"study_id": 106104, "supplement_id": 872, "safety_score": "85", "efficacy_score": 45, "quality_score": 90, "study_goal": "The researchers aimed to determine whether Alpha-Linolenic Acid (ALA) supplementation affects serum prostate-specific antigen (PSA) levels, a biomarker for prostate cancer.", "results_summary": "The study found that ALA supplementation (2 g/day) increased PSA levels by 0.10 ng/mL compared to placebo, but the difference was not statistically significant (P=0.12). The confidence interval included no effect, suggesting more research is needed to confirm any clinical impact.", "population_specificity": "1622 male patients aged 60-80 years with a history of myocardial infarction and initial PSA <4 ng/mL.", "effective_dosage": "2 g per day of ALA in margarine spreads.", "study_duration": "40 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:48.898941+00:00"}
{"study_id": 106105, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if cheek cell fatty acid composition reflects ALA supplementation from linseed oil and correlates with blood fractions' fatty acid profiles.", "results_summary": "The study found that linseed oil increased ALA and its long-chain n-3 metabolites in cheek cells, with changes correlating to blood fractions, suggesting cheek cells as a non-invasive biomarker for n-3 PUFA intake and metabolism.", "population_specificity": "38 subjects in a randomized, controlled, double-blind human intervention study.", "effective_dosage": "17 g/d of an ALA-rich linseed oil mixture or olive oil.", "study_duration": "8-week intervention period (after a 2-week run-in).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:49.004737+00:00"}
{"study_id": 106107, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the effects of n-3 fatty acids, including ALA, on adult hippocampal neurogenesis and neuroplasticity, and their potential therapeutic use for neurodegenerative diseases.", "results_summary": "The study found that n-3 fatty acids, including ALA, enhance adult hippocampal neurogenesis, promote synaptic plasticity, and may protect neurons in neurological diseases, with potential benefits for cognition and mood regulation.", "population_specificity": "Not specified (general review of n-3 fatty acids' effects on mammalian brain processes).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:54.140539+00:00"}
{"study_id": 106109, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize the evidence regarding the relationship between Alpha-Linolenic Acid (ALA) and cardiovascular disease (CVD) risk through a meta-analysis.", "results_summary": "Higher ALA exposure was associated with a moderately lower risk of CVD, with significant results for dietary ALA but nonsignificant trends for biomarker studies. The findings were consistent across study types but highlighted unexplained heterogeneity.", "population_specificity": "251,049 individuals from 27 original studies, including both prospective and retrospective designs.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:54.657955+00:00"}
{"study_id": 106106, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether plant-derived Alpha-Linolenic Acid (ALA), alone or combined with marine n-3 fatty acids (EPA and DHA), reduces systemic inflammation (measured via hsCRP) in post-myocardial infarction patients.", "results_summary": "The study found that ALA supplementation (1.98 g/day) did not significantly affect hsCRP levels (-5% vs. placebo, p=0.37). Combining ALA with EPA-DHA also showed no significant impact (-3% vs. placebo, p=0.62).", "population_specificity": "Patients aged 60\u201380 years (79% male) with a history of myocardial infarction.", "effective_dosage": "1.98 g/day ALA (via margarine).", "study_duration": "40 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:54.913547+00:00"}
{"study_id": 106108, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how varying LA:ALA ratios in soybean oils affect T cell proliferation and inflammatory responses in older adults.", "results_summary": "Higher T cell proliferative responses were observed with LA:ALA ratios \u2264 9.69, particularly at 8.70, while ratios >10 showed no significant change. The effects were independent of inflammatory cytokine production.", "population_specificity": "Older adults (>50 y) with elevated LDL cholesterol (3.37-4.14 mmol/L).", "effective_dosage": "30% of energy as fat, two-thirds of which was the experimental oil (varying LA:ALA ratios).", "study_duration": "35 days per diet.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:54.974516+00:00"}
{"study_id": 106111, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether adding walnuts (a source of ALA) to a Western-style diet would improve semen quality in healthy young men.", "results_summary": "The study found that ALA from walnuts improved sperm vitality, motility, and morphology, and increased serum omega-3 levels, including ALA. Sperm ALA levels were inversely correlated with sperm aneuploidy, particularly sex chromosome nullisomy.", "population_specificity": "117 healthy men aged 21-35 years who routinely consumed a Western-style diet.", "effective_dosage": "75 g of whole-shelled walnuts per day.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:56.341486+00:00"}
{"study_id": 106113, "supplement_id": 872, "safety_score": "90", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the impact of an ALA, FOS, and inulin-enriched cookie on cardiovascular risk factors in obese patients.", "results_summary": "The study found that ALA intake significantly increased soluble fiber and ALA levels, leading to reduced total cholesterol, LDL cholesterol, and C-reactive protein in obese males, with no gastrointestinal adverse effects.", "population_specificity": "Obese patients (36 initially, 15 per group completed the study).", "effective_dosage": "3.2 grams per day of ALA (via enriched cookie).", "study_duration": "1 month.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:56.639943+00:00"}
{"study_id": 106110, "supplement_id": 872, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of walnut consumption (rich in ALA) and fish consumption on markers of inflammation and endothelial activation.", "results_summary": "The walnut diet increased plasma phospholipid ALA by 140% and reduced arachidonic acid by 7%, while also inhibiting E-selectin by 12.7% relative to the fish diet. However, it showed no significant effects on other inflammatory markers like IL-1\u03b2, IL-6, TNF-\u03b1, or CRP.", "population_specificity": "25 normal to mildly hyperlipidemic men and women.", "effective_dosage": "42.5 g of walnuts per 10.1 mJ, 6 times per week (1.8% of energy as n-3 fat).", "study_duration": "4 weeks per diet.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:56.756051+00:00"}
{"study_id": 106114, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether statins modify the effects of n-3 fatty acids, including ALA, on major cardiovascular events in post-MI patients.", "results_summary": "In statin non-users, ALA combined with EPA-DHA reduced major cardiovascular events (9% vs. 18% in placebo), suggesting potential efficacy. No significant effect was observed in statin users.", "population_specificity": "Patients with a history of myocardial infarction (MI), divided into statin users and non-users.", "effective_dosage": "2 g ALA daily (combined with 400 mg EPA-DHA in one group).", "study_duration": "Not specified in the abstract.", "interactions": "Statins may modify the effects of n-3 fatty acids.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:57.932545+00:00"}
{"study_id": 106115, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether increased intake of ALA, EPA, and DHA could reduce ventricular arrhythmias and fatal MI in high-risk post-MI patients with diabetes.", "results_summary": "The study found that ALA, combined with EPA and DHA, significantly reduced ventricular arrhythmia-related events and fatal MI, with hazard ratios of 0.16 and 0.28, respectively, compared to placebo.", "population_specificity": "Post-MI patients with diabetes, aged 60-80 years.", "effective_dosage": "1.9 g ALA daily (via margarine).", "study_duration": "40 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:01.922312+00:00"}
{"study_id": 106117, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether dietary supplementation with Alpha-Linolenic Acid (ALA) could slow cognitive decline in coronary heart disease patients.", "results_summary": "The study found no significant effect of ALA supplementation on cognitive decline, as measured by changes in MMSE scores or risk of dementia, compared to placebo. The results were statistically non-significant and clinically irrelevant.", "population_specificity": "Coronary heart disease patients (78% men) aged 60 to 80 years.", "effective_dosage": "2 g/d of ALA.", "study_duration": "40 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:02.702224+00:00"}
{"study_id": 106116, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the effect of combining different doses of micronutrients and n-3 fatty acids (including ALA) on reducing morbidity in schoolchildren.", "results_summary": "High n-3 fatty acid supplementation (including 900 mg ALA) significantly reduced episodes and duration of upper respiratory tract infections, lower respiratory tract infections, gastrointestinal complaints, and general symptoms compared to low n-3 fatty acid supplementation. The high micronutrient intervention also reduced the duration of general symptoms.", "population_specificity": "Schoolchildren aged 6-10 years in Bangalore, India.", "effective_dosage": "High n-3 fatty acids: 900 mg ALA + 100 mg docosahexaenoic acid; low n-3 fatty acids: 140 mg ALA.", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:03.699258+00:00"}
{"study_id": 106119, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether prenatal DHA supplementation affects ALA concentrations in breast milk at 1 month postpartum.", "results_summary": "The study found that prenatal DHA supplementation significantly increased ALA concentrations in breast milk (1.38 \u00b1 0.47 vs. 1.24 \u00b1 0.46, P = 0.01), suggesting a potential benefit for breast-fed infants.", "population_specificity": "Pregnant women in Mexico, supplemented from 18-22 weeks gestation to parturition.", "effective_dosage": "400 mg DHA daily.", "study_duration": "From 18-22 weeks gestation to parturition.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:04.197929+00:00"}
{"study_id": 106121, "supplement_id": 872, "safety_score": "85", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the relationship between dietary ALA intake, tissue concentrations, and cardiovascular health in humans, focusing on its potential cardioprotective effects.", "results_summary": "Short-term trials showed inconsistent or no effects of ALA on blood lipids, inflammation, and glucose metabolism. Observational evidence suggested a protective effect against nonfatal myocardial infarction, but no benefits were observed for heart failure, atrial fibrillation, or sudden death.", "population_specificity": "Generally healthy participants and cardiac patients (implied in long-term trial context).", "effective_dosage": "1.2-3.6 g/d", "study_duration": "6-12 weeks (short-term trials)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:05.296822+00:00"}
{"study_id": 106122, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore how genetic polymorphisms influence the health effects of ALA and other polyunsaturated fatty acids, focusing on metabolism and disease risk.", "results_summary": "The study found that genetic differences in FADS1 and FADS2 enzymes affect ALA metabolism and its health outcomes, including potential impacts on infant IQ, atopy, and coronary heart disease risk. It also highlighted the need to consider genetic variants in future intervention studies.", "population_specificity": "General population, with specific mentions of pregnancy, lactation, and infants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:05.788121+00:00"}
{"study_id": 106120, "supplement_id": 872, "safety_score": "85", "efficacy_score": 45, "quality_score": 90, "study_goal": "The researchers aimed to determine whether Alpha-Linolenic Acid (ALA) supplementation reduces the rate of major cardiovascular events in post-myocardial infarction patients receiving standard therapy.", "results_summary": "ALA supplementation (1.9 g/day) did not significantly reduce major cardiovascular events overall, though a trend toward benefit was observed in women. The hazard ratio for ALA was 0.91 (95% CI, 0.78\u20131.05; P=0.20).", "population_specificity": "Patients aged 60\u201380 years (78% men) who had a prior myocardial infarction and were on antihypertensive, antithrombotic, and lipid-modifying therapy.", "effective_dosage": "1.9 g of ALA daily via margarine.", "study_duration": "40 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:07.005147+00:00"}
{"study_id": 106123, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the polyunsaturated fatty acid (PUFA) composition, including ALA, in blood plasma and spermatozoa of infertile men with idiopathic oligoasthenoteratozoospermia (OAT) compared to fertile men.", "results_summary": "Infertile men had lower levels of omega-3 fatty acids, including ALA, in spermatozoa compared to fertile men, with higher omega-6/omega-3 ratios negatively correlating with sperm count, motility, and morphology. The study suggests potential benefits of omega-3 supplementation for improving fertility in men with idiopathic OAT.", "population_specificity": "Infertile men with idiopathic oligoasthenoteratozoospermia (OAT) and fertile men as controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:11.733157+00:00"}
{"study_id": 106118, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether elevated serum levels of Alpha-Linolenic Acid (ALA) are associated with pregnancy outcomes in women undergoing IVF.", "results_summary": "Elevated serum ALA levels were associated with a decreased chance of pregnancy in women undergoing IVF, with the highest quartile showing significantly lower odds compared to the lowest quartile. The association remained significant after adjusting for confounding factors.", "population_specificity": "Ninety-one women undergoing IVF at a university hospital.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:11.904340+00:00"}
{"study_id": 201671, "supplement_id": 872, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to assess the cardiovascular and metabolic effects of camelina oil (a source of ALA) in hypertensive patients with metabolic syndrome.", "results_summary": "Camelina oil supplementation increased ALA and EPA levels but did not improve vascular function. It adversely affected glucose metabolism, increasing fasting glycemia and HOMA-IR index, without altering plasma lipids or inflammatory markers.", "population_specificity": "Treated essential hypertensive patients with metabolic syndrome.", "effective_dosage": "\u22481.5 g ALA/day", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:12.051241+00:00"}
{"study_id": 201669, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to analyze the potential of Alpha-Linolenic Acid (ALA) to modulate inflammatory status and dyslipidemic conditions in patients with autoimmune disorders, particularly Juvenile Systemic Connective Tissue Diseases (JSCTD).", "results_summary": "The study found that ALA supplementation reduced inflammatory parameters such as IL-6, CRP, and fasting glucose in subjects with dyslipidemia, suggesting a positive effect on both inflammation and lipid profiles in autoimmune disorders.", "population_specificity": "Children and adolescents with Juvenile Systemic Connective Tissue Diseases (JSCTD) and associated dyslipidemia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:12.064488+00:00"}
{"study_id": 201670, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of vegetable-sourced ALA supplementation on inflammatory markers and lipid profiles in individuals with chronic kidney disease (CKD).", "results_summary": "ALA supplementation significantly reduced C-reactive protein (CRP), an inflammatory marker, but had no significant effect on total cholesterol, HDL, LDL, or triglycerides in CKD patients.", "population_specificity": "Adult or elderly patients with CKD, including those receiving dialysis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:12.227886+00:00"}
{"study_id": 201672, "supplement_id": 872, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of ALA and DHA supplementation on plasma oxylipin concentrations, including time course and sex differences.", "results_summary": "ALA supplementation doubled plasma ALA concentrations but had no significant effect on ALA oxylipins after 28 days, whereas DHA supplementation significantly increased both DHA and its oxylipins. The study found that DHA had greater and earlier effects on oxylipins, particularly in females.", "population_specificity": "Healthy men and women aged 19-34 with a BMI of 18-28 kg/m\u00b2.", "effective_dosage": "~4 g/d of ALA or DHA.", "study_duration": "28 days of supplementation, with >6-week wash-in and wash-out phases.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:14.439895+00:00"}
{"study_id": 201673, "supplement_id": 872, "safety_score": "30", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine the associations of EPA-DHA and ALA intakes with graft failure and all-cause mortality in renal transplant recipients (RTR).", "results_summary": "ALA intake was significantly associated with increased mortality in RTR, with those in the highest tertile of ALA intake exhibiting about a 2-fold higher mortality risk compared to the lowest tertile. No significant association was found between ALA intake and graft failure.", "population_specificity": "Renal transplant recipients (637 participants).", "effective_dosage": "Per 0.1 energy% difference (specific amounts not detailed).", "study_duration": "Median follow-up of 3.1 years (interquartile range 2.7, 3.8).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:14.707106+00:00"}
{"study_id": 221, "supplement_id": 873, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of a transdermal patch containing calcium citrate nanoparticle-encapsulated Alpha-Lipoic Acid (ALA) in reducing subcutaneous fat accumulation in overweight individuals.", "results_summary": "The study found that the ALA transdermal patch significantly reduced triceps skinfold and subcutaneous fat thickness but did not significantly alter arm circumference or most blood lipid levels, except for a reduction in total cholesterol.", "population_specificity": "Overweight participants (average age 37.96 \u00b1 7.80 years, n=116).", "effective_dosage": "Not specified in the abstract.", "study_duration": "2 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:15.731537+00:00"}
{"study_id": 225, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of Alpha-Lipoic Acid (ALA) as a therapeutic option for kidney diseases, focusing on its antioxidant properties and molecular mechanisms.", "results_summary": "The study suggests ALA shows clinical promise in treating kidney diseases by activating protective mechanisms and inhibiting harmful pathways, potentially offering a safer alternative to current treatments with fewer adverse effects.", "population_specificity": "Patients with kidney diseases (specific conditions not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:18.943840+00:00"}
{"study_id": 223, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether short-term intravenous administration of Alpha-Lipoic Acid (ALA) could improve pain intensity and biomarkers of DNA damage in diabetic subjects.", "results_summary": "ALA treatment significantly reduced pain intensity and plasma 8-OHdG levels in diabetic subjects, but no changes were observed in sister-chromatid exchanges or micronucleated lymphocytes.", "population_specificity": "Sixteen diabetic subjects (six type 1 and ten type 2) and sixteen nondiabetic controls matched by sex and age.", "effective_dosage": "600 mg daily", "study_duration": "4 to 9 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:19.619366+00:00"}
{"study_id": 224, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether alpha-lipoic acid (ALA) can effectively mitigate the toxic effects of metals like aluminum, arsenic, lead, mercury, and cadmium through its antioxidant and chelating properties.", "results_summary": "ALA supplementation significantly enhanced cellular defense mechanisms and antioxidant enzyme activity, effectively mitigating toxicity from aluminum, arsenic, and cadmium, though its efficacy against lead and mercury was more limited. Overall, ALA showed promise as an alternative for alleviating metal toxicity.", "population_specificity": "Not specified (review of existing studies)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:20.007167+00:00"}
{"study_id": 222, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could protect dopaminergic neurons in the substantia nigra pars compacta (SNc) from ferroptotic damage induced by ultrafine diesel exhaust particles (ufDEP).", "results_summary": "ALA treatment effectively reduced iron accumulation, decreased lipid peroxidation, and restored antioxidant levels, protecting tyrosine hydroxylase (TH)-positive neurons from ufDEP-induced ferroptotic damage. The results suggest ALA has potential as a therapeutic intervention for Parkinson's disease (PD).", "population_specificity": "Mice exposed to ultrafine diesel exhaust particles (ufDEP).", "effective_dosage": "Not specified (intraperitoneal injection).", "study_duration": "Seven consecutive days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:20.162337+00:00"}
{"study_id": 226, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combining alpha-lipoic acid (ALA) with sildenafil citrate (SC) improves sperm quality during freeze-thawing in asthenozoospermic men.", "results_summary": "The study found that ALA, especially when combined with SC, significantly reversed freeze-thaw-induced sperm damage, reducing oxidative stress, inflammation, and apoptosis while improving sperm quality markers. The combination also partially prevented premature acrosome reactions caused by SC.", "population_specificity": "Asthenozoospermic men (30 semen samples analyzed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Sildenafil citrate (SC) was noted to interact with ALA, enhancing sperm quality but inducing premature acrosome reactions, which ALA partially mitigated.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:21.029303+00:00"}
{"study_id": 229, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) improves joint function, inflammatory markers, oxidative stress, and glycemic control in patients with comorbid osteoarthritis (OA) and type 2 diabetes mellitus (T2DM).", "results_summary": "ALA administration led to statistically significant improvements in WOMAC pain scores, the Lequesne Algofunctional Index, and the AIMS-P compared to the control group, indicating benefits for joint function and pain in comorbid OA and T2DM patients.", "population_specificity": "Patients with comorbid osteoarthritis and type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:23.344675+00:00"}
{"study_id": 228, "supplement_id": 873, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could improve symptoms and biomarkers of diabetic peripheral neuropathy (DPN) through its antioxidant and anti-inflammatory effects.", "results_summary": "ALA significantly improved vibration perception threshold (VPT), neuropathy symptoms (NTSS-6), quality of life (SF-12), oxidative stress biomarkers (MDA, NO, GSH), and inflammatory biomarkers (hs-CRP) compared to placebo, with no serious adverse events reported.", "population_specificity": "52 subjects (22 males, 30 females) with diabetic peripheral neuropathy, mean age 55.63 \u00b1 7.5 years, on gabapentin or pregabalin.", "effective_dosage": "600 mg oral once daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:23.623355+00:00"}
{"study_id": 227, "supplement_id": 873, "safety_score": "30", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combining intravenous alpha-lipoic acid (ALA) with high-dose intravenous vitamin C (IVC) in cancer treatment increases toxicity or affects therapeutic outcomes.", "results_summary": "ALA alone showed no anticancer activity and did not influence hydrogen peroxide formation from IVC. Combining ALA with IVC increased toxicity in mice and dampened IVC's tumor growth inhibition at lower ALA doses. Higher ALA doses did not enhance IVC's effects.", "population_specificity": "Human cancer cell lines (6 types) and mouse xenografts of metastatic breast cancer (MDA-MB-231).", "effective_dosage": "ALA (0.25, 0.5, 1 mM in vitro; 10, 20, 50 mg/kg in mice), IVC (0.625-20 mM in vitro; 0.2, 0.5, 4 g/kg in mice).", "study_duration": "Prolonged treatment (exact duration not specified).", "interactions": "ALA dampened IVC's prooxidative effects and increased toxicity when combined.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:25.420579+00:00"}
{"study_id": 230, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic effects of Alpha-Lipoic Acid (LA) on obesity-induced memory impairment and neurochemical changes in rats.", "results_summary": "LA treatment improved memory, reduced BMI, and alleviated neurochemical and histopathological changes in obese rats, demonstrating antioxidant and anti-inflammatory properties. No synergistic effect was observed between LA and caffeine-loaded chitosan nanoparticles (CCNPs).", "population_specificity": "Obese rats induced by a high-fat diet.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:26.025992+00:00"}
{"study_id": 234, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could ameliorate hormonal dysfunction in ovarian granulosa cells (GCs) induced by advanced glycation end-products (AGEs).", "results_summary": "ALA treatment reversed AGEs-induced changes in steroidogenic enzyme expression and hormone secretion, likely by reducing RAGE expression, suggesting potential therapeutic benefits for ovarian dysfunction.", "population_specificity": "Isolated ovarian granulosa cells (GCs) from human subjects.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.286062+00:00"}
{"study_id": 233, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to examine the nephroprotective effects of Alpha-Lipoic Acid (ALA) in vitro and its impact on reactive sulfur species (RSS) production in chronic kidney disease (CKD) patients.", "results_summary": "ALA improved HEK293 cell viability under hypoxic conditions to normoxic levels. In CKD patients, ALA supplementation increased reactive sulfane sulfur levels but did not affect oxidative stress parameters.", "population_specificity": "Human embryonic kidney cells (HEK293) in vitro and chronic kidney disease (CKD) patients (non-dialyzed and undergoing peritoneal dialysis).", "effective_dosage": "Not specified", "study_duration": "30 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.287508+00:00"}
{"study_id": 231, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of Alpha-Lipoic Acid (LA) loaded in an in situ gel-forming oil (LGF) for promoting wound healing and reducing inflammation in oral mucositis caused by chemoradiotherapy.", "results_summary": "LA-LGF demonstrated strong wound-healing properties, reduced inflammation by inhibiting proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1, IL-6), and improved mucosal edema and granulation in rats with 5-fluorouracil-induced oral mucositis. The gel-forming oil also provided sustained release of LA, enhancing its antioxidative effects.", "population_specificity": "Rats with 5-fluorouracil-induced oral mucositis.", "effective_dosage": "Solubility of LA in LGF oil was above 100 mg/mL (exact dosage not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.985989+00:00"}
{"study_id": 232, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to study the antitumor effects of Alpha-Lipoic Acid (ALA) in liver-cancer derived cell lines, focusing on its role in AMPK signaling and its impact on cell migration, invasion, and epithelial-mesenchymal transition (EMT).", "results_summary": "ALA significantly inhibited cell migration/invasion in HepG2/C3A cells, dependent on AMPK activation and p53 nuclear compartmentalization. The anti-invasive effect was abrogated in TP53-silenced cells, and ALA inhibited EMT in control HepG2/C3A but not in TP53-deficient or Hep3B cells.", "population_specificity": "Liver-cancer derived cell lines (HepG2/C3A and Hep3B).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:29.050733+00:00"}
{"study_id": 235, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the cardiovascular and renal effects of Alpha-Lipoic Acid (LA) in a two-kidney-one-clip (2K1C) hypertension model.", "results_summary": "LA treatment mitigated the increased vascular contraction induced by hypertension but did not reverse cardiac mass changes, kidney weight imbalances, or improve vasorelaxation. Urea and creatinine levels remained unaffected by LA.", "population_specificity": "Rats with induced hypertension (2K1C model).", "effective_dosage": "Not specified", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.645953+00:00"}
{"study_id": 236, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to describe the chemical and biological functions of Alpha-Lipoic Acid (ALA) in the cancer environment, including its mechanisms in tumor prevention, anticancer activity, and adjunctive therapy roles.", "results_summary": "The study found that ALA exhibits distinct pro-oxidative properties in cancer cells compared to normal cells, influencing carcinogenic and anti-carcinogenic pathways. It also highlighted ALA's potential roles in nanomedicine, hypoxia-inducible factors, and cancer stem cell research.", "population_specificity": "Not specified (general cancer research context).", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:31.117798+00:00"}
{"study_id": 237, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of \u03b1-lipoic acid (R enantiomer) supplementation on maternal and fetal metabolic health in pregnancies complicated by maternal obesity.", "results_summary": "LA supplementation reduced maternal weight gain, improved glycemic control, and increased cholesterol concentrations in mothers, while fetuses showed lower body weight, improved insulin sensitivity, and altered lipid metabolism, though concerns about liver cholesterol and triglyceride accumulation were noted.", "population_specificity": "Female Sprague-Dawley rats with obesity-inducing diets during prepregnancy and gestation.", "effective_dosage": "0.25% LA in the diet.", "study_duration": "3 weeks prepregnancy + 20 days gestation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:33.876369+00:00"}
{"study_id": 238, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the combination of exemestane and \u03b1-lipoic acid as a novel treatment for ER-positive breast cancer, focusing on HDAC inhibition and antiproliferative effects.", "results_summary": "\u03b1-lipoic acid showed HDAC inhibitory activity, particularly for HDAC6, and synergistic antiproliferative effects when combined with exemestane. It also increased mitochondrial fusion, upregulated apoptosis-related proteins, and downregulated anti-apoptotic proteins.", "population_specificity": "ER-positive breast cancer cells (in vitro study).", "effective_dosage": "Not specified (IC50 values in the 3-digit micromolar range).", "study_duration": "24 hours to 10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:34.478055+00:00"}
{"study_id": 240, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could mitigate oxidative stress and improve testicular function in varicocele and AGEs animal models.", "results_summary": "ALA administration helped counteract abnormal sperm parameters, testicular dysfunction, and altered protein expression caused by AGEs and varicocele, showing slightly greater overall benefit than ALT711, though the difference was not statistically significant.", "population_specificity": "Animal models (varicocele and AGEs)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.715775+00:00"}
{"study_id": 239, "supplement_id": 873, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of Alpha-Lipoic Acid (ALA) as a treatment for neuropathic pain and compare it to traditional pharmaceuticals.", "results_summary": "The study found that ALA significantly improves neuropathic pain and nerve conduction velocity, with efficacy comparable to existing pharmaceuticals. Common side effects were dose-dependent and included nausea, vomiting, and vertigo, but overall safety was acceptable.", "population_specificity": "Patients with neuropathic pain, including chemotherapy-induced peripheral neuropathy, entrapment neuropathies, radicular nerve pain, and burning mouth syndrome.", "effective_dosage": "600 mg/day", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.388305+00:00"}
{"study_id": 242, "supplement_id": 873, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could protect against gliclazide-induced hepatotoxicity in type 2 diabetic models.", "results_summary": "ALA significantly reduced high glucose and gliclazide-induced liver cell death in vitro and prevented liver damage in diabetic rats by suppressing inflammation, apoptosis, and activating antioxidant pathways.", "population_specificity": "Type 2 diabetic rats and human liver cells (HL-7702).", "effective_dosage": "60 mg/kg ALA in rats.", "study_duration": "6 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.475830+00:00"}
{"study_id": 241, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could protect against UV-A and UV-B-induced skin damage in rats.", "results_summary": "ALA significantly reduced oxidative stress markers (TOS and OSI) and apoptotic cells in UV-irradiated rats, demonstrating protective effects against UV-induced skin damage. The stereological findings also showed favorable changes in skin structure with ALA treatment.", "population_specificity": "Rats subjected to UV-A and UV-B irradiation.", "effective_dosage": "100 mg/kg/day administered via gavage.", "study_duration": "One month (2 hours of UV irradiation per day).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.885862+00:00"}
{"study_id": 243, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate whether Alpha-Lipoic Acid (ALA) reduces amyloidogenic effects of amyloid-\u03b2 precursor protein (APP) in a transgenic mouse model of Alzheimer's disease and to study the underlying mechanism.", "results_summary": "ALA administration reduced amyloid plaque pathology and cognitive impairment in APP23/PS45 mice, increased ADAM10 expression, and promoted non-amyloidogenic APP processing. It also enhanced mitophagy, which facilitated ADAM10 maturation and \u03b1-cleavage of APP.", "population_specificity": "APP23/PS45 transgenic mice (a model for Alzheimer's disease) and 20E2 cells in vitro.", "effective_dosage": "Not specified in the abstract.", "study_duration": "4 months (in mice).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:41.388311+00:00"}
{"study_id": 245, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether Alpha-Lipoic Acid (ALA) could mitigate gentamicin-induced nephrotoxicity in rats.", "results_summary": "ALA significantly reduced KIM-1 levels and showed partial reductions in urine creatinine levels. It also decreased NRF-2, CAS-3, and NR4A2 expressions, but did not affect NF-B expression.", "population_specificity": "Wistar albino rats", "effective_dosage": "100 mg/kg", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.166034+00:00"}
{"study_id": 244, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine the efficacy of \u03b1-lipoic acid (\u03b1-Lipo) in mitigating drought stress effects on grapevine rootstocks, comparing its impact on drought-tolerant and drought-sensitive varieties.", "results_summary": "\u03b1-Lipo improved physiological parameters, proline content, and antioxidant enzyme activities while reducing oxidative stress markers in grapevines under drought conditions, with efficacy varying by rootstock type and concentration (1\u201350 \u03bcM).", "population_specificity": "American grapevine rootstocks '1103 P' (drought-tolerant) and '3309 C' (drought-sensitive).", "effective_dosage": "0, 1, 25, and 50 \u03bcM (foliar application).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:42.765178+00:00"}
{"study_id": 246, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether exogenous \u03b1-lipoic acid (\u03b1-LA) treatment could reduce enzymatic browning and maintain nutritional quality in fresh-cut pears.", "results_summary": "The study found that 0.5 g/L \u03b1-LA treatment effectively maintained color and firmness, inhibited microbial growth, reduced oxidative stress markers (MDA and H2O2), decreased PPO activity, enhanced antioxidant enzyme activities (SOD, CAT, PAL), and upregulated phenolic and carbohydrate metabolism-related gene expression, leading to higher total phenols, flavonoids, and sucrose content.", "population_specificity": "Fresh-cut pear fruit", "effective_dosage": "0.5 g/L", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:44.427588+00:00"}
{"study_id": 249, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could protect against rhabdomyolysis-induced acute kidney injury (AKI) in rats by reducing oxidative stress and inflammation.", "results_summary": "ALA treatment improved kidney histological and biochemical abnormalities, reduced oxidative stress markers (malondialdehyde, NGAL, TNF-\u03b1), and restored glutathione levels in rats with rhabdomyolysis-induced AKI.", "population_specificity": "Rats (six groups, n=6 per group)", "effective_dosage": "5, 10, and 20 mg/kg (intraperitoneal administration)", "study_duration": "Four consecutive days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.565325+00:00"}
{"study_id": 248, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether alpha-lipoic acid (ALA) supplementation during early pregnancy could mitigate preeclampsia-like symptoms in stroke-prone spontaneously hypertensive rats (SHRSP).", "results_summary": "ALA supplementation prevented pregnancy-dependent blood pressure rise, improved renal function, enhanced fetal growth, and reduced oxidative stress markers and sFlt1 levels, indicating improved placental function and fetal outcomes.", "population_specificity": "Pregnant stroke-prone spontaneously hypertensive rats (SHRSP).", "effective_dosage": "25 mg/kg body weight, administered intraperitoneally on gestation days 1, 8, and 12.", "study_duration": "Administered during early pregnancy (gestation days 1, 8, and 12).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.909356+00:00"}
{"study_id": 247, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Alpha-Lipoic Acid (ALA) could reduce lipid accumulation and improve lipid metabolism in an in vitro model of nonalcoholic fatty liver disease (NAFLD).", "results_summary": "ALA significantly reduced lipid droplets and altered fatty acid profiles in HepG2 cells, with concentration-dependent effects. It also modulated genes involved in cholesterol biosynthesis, LDL metabolism, and PPAR pathways, suggesting a role in lipid homeostasis and energy dissipation.", "population_specificity": "HepG2 cells (in vitro model of NAFLD)", "effective_dosage": "1 \u00b5M and 5 \u00b5M", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.957577+00:00"}
{"study_id": 250, "supplement_id": 873, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the potential of newly discovered chrysin derivatives, particularly compound 4b, as therapeutic agents for inflammatory bowel disease (IBD).", "results_summary": "Compound 4b significantly inhibited monocyte adhesion to colon epithelium, reduced ROS production, downregulated ICAM-1 and MCP-1 expression, and suppressed NF-\u03baB activity. In vivo, it showed dose-dependent inhibition of TNBS-induced colitis in rats.", "population_specificity": "Rats with TNBS-induced colitis (animal model).", "effective_dosage": "Not specified (IC50 value of 4.71 \u03bcM for in vitro effects).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.037878+00:00"}
